



OECD Series on Adverse Outcome Pathways No. 18

Adverse Outcome Pathway  
on inhibition of calcineurin  
activity leading to impaired  
T-cell dependent antibody  
response

**Hiroyuki Komatsu,  
Junichiro Sugimoto,  
Ken Goto,  
Kiyoshi Kushima,  
Naohisa Tsutsui,  
Shigeru Hisada,  
Shiho Ito,  
Tadashi Kosaka,  
Takumi Ohishi,  
Yasuharu Otsubo,  
Yoshihiro Takahashi**

<https://dx.doi.org/10.1787/3c988dde-en>

# Adverse Outcome Pathway on Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response

Series on Adverse Outcome Pathways No. 18

AOP No. 154 in the [AOP Wiki platform](#)

# Foreword

This Adverse Outcome Pathway (AOP) on Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response, has been developed under the auspices of the OECD AOP Development Programme, overseen by the Extended Advisory Group on Molecular Screening and Toxicogenomics (EAGMST), which is an advisory group under the Working Party of the National Coordinators for the Test Guidelines Programme (WNT). The AOP has been reviewed internally by the EAGMST, externally by experts nominated by the WNT, and has been endorsed by the WNT and the Working Party on Hazard Assessment (WPHA) on 22 July 2021.

Through endorsement of this AOP, the WNT and the WPHA express confidence in the scientific review process that the AOP has undergone and accept the recommendation of the EAGMST that the AOP be disseminated publicly. Endorsement does not necessarily indicate that the AOP is now considered a tool for direct regulatory application.

The OECD's Chemicals and Biotechnology Committee agreed to declassification of this AOP on 7 October 2021.

This document is being published under the responsibility of the OECD's Chemicals and Biotechnology Committee.

The outcome of the internal and external reviews are publicly available respectively in the [AOP Wiki](#) and the [eAOP Portal of the AOP Knowledge Base](#) at the following links: [[internal review](#)] [[external review](#)].

# Authors:

Hiroyuki Komatsu (1) Junichiro Sugimoto (1) Ken Goto (1) Kiyoshi Kushima (1) Naohisa Tsutsui (1) Shigeru Hisada (1) Shiho Ito (1) Tadashi Kosaka (1) Takumi Ohishi (1) Yasuharu Otsubo (1) Yoshihiro Takahashi (1)

(1) AOP Working Group, Testing Methodology Committee, The Japanese Society of Immunotoxicology

Corresponding author: Takumi Ohishi ([ohishi@bozo.co.jp](mailto:ohishi@bozo.co.jp))

# Abstract

Calcineurin (CN), a protein phosphatase, is known to impair immune function when its phosphatase activation is inhibited. The relationship between CN and immune functions is well understood, and immunosuppressants that work by inhibiting CN have been developed.

CN inhibitors (CNIs) inhibit CN phosphatase activity to suppress many kinds of immune functions and have been used to prevent hyper immune reactions such as rejection and graft versus host disease (GVHD), and treat autoimmune and allergic disorders such as psoriasis and atopic dermatitis. On the other hand, CNIs are reported to induce immunosuppression-derived adverse effects such as increased frequency and/or severity of infections and increased tumor incidences. CNIs might affect several T-cell derived immune functions to induce compromised host. Among the affected immune functions, T-cell dependent antibody response (TDAR) is an important factor to resist infections and thought to be the useful endpoint on evaluating immunotoxicity of chemicals; therefore, this AOP describes the linkage between the inhibition of CN activity and impairment of TDAR.

CN activity is inhibited when stressors bind to CN with their respective immunophilins, which interferes with the nuclear localization of nuclear factor of activated T cells (NFAT), a substrate of CN. As a result, the formation of functional NFAT complexes with activator protein-1 (AP-1) that bind at the site of IL-2, IL-4 and other T cell -derived cytokine promoters is reduced, thereby suppressing production of these cytokines. Among the affected cytokines from each of the helper T cell subsets, reduced production of IL-2 and IL-4 affects the proliferation and differentiation of B-cells to suppress TDAR.

We have identified a number of key events along this pathway and determined the key event relationships, based on which we have created an AOP for inhibition of CN activity leading to impaired TDAR.

Since CN is produced in a vast variety of species, this AOP might be applicable to many mammal species, including humans and rodents.

## *Contents*

|   |           |
|---|-----------|
| <b>Background .....</b>   | <b>3</b>  |
| <b>Graphical Representation.....</b>  | <b>3</b>  |
| <b>Summary of the AOP .....</b>   | <b>3</b>  |
| Events.....   | 3         |
| Key Event Relationships .....   | 4         |
| <b>Overall Assessment of the AOP.....</b>   | <b>5</b>  |
| Domain of Applicability .....   | 5         |
| Essentiality of the Key Events .....  | 6         |
| Weight of Evidence Summary .....  | 7         |
| Quantitative Understanding .....  | 13        |
| <b>Considerations for Potential Applications of the AOP (optional) .....</b>  | <b>14</b> |
| <b>Appendix 1 - MIE, KEs and AO.....</b>  | <b>19</b> |
| List of MIEs in this AOP .....  | 19        |
| Event: 980: Inhibition, Calcineurin Activity ( <a href="https://aopwiki.org/events/980">https://aopwiki.org/events/980</a> ) .....  | 19        |
| Evidence for Perturbation by Stressor .....   | 20        |
| Domain of Applicability.....  | 20        |
| Key Event Description .....   | 21        |
| How it is Measured or Detected .....  | 21        |
| List of Key Events in the AOP.....  | 22        |
| Event: 979: Interference, nuclear localization of NFAT ( <a href="https://aopwiki.org/events/979">https://aopwiki.org/events/979</a> ).....   | 22        |
| Domain of Applicability.....  | 24        |
| Key Event Description.....  | 24        |
| How it is Measured or Detected .....  | 24        |
| Event: 981: Reduction, NFAT/AP-1 complex formation ( <a href="https://aopwiki.org/events/981">https://aopwiki.org/events/981</a> ).....   | 26        |
| Domain of Applicability.....  | 27        |
| Key Event Description.....  | 27        |
| How it is Measured or Detected .....  | 27        |
| Event: 1202: Suppression, IL-2 and IL-4 production ( <a href="https://aopwiki.org/events/1202">https://aopwiki.org/events/1202</a> ) .....  | 28        |
| Domain of Applicability.....  | 29        |
| Key Event Description.....  | 29        |
| How it is Measured or Detected .....  | 30        |
| List of Adverse Outcomes in this AOP .....  | 32        |
| Event: 984: Impairment, T-cell dependent antibody response ( <a href="https://aopwiki.org/events/984">https://aopwiki.org/events/984</a> ).....   | 32        |
| Domain of Applicability.....  | 32        |
| Key Event Description.....  | 33        |
| How it is Measured or Detected .....  | 34        |
| Regulatory Significance of the AO .....   | 35        |
| <b>Appendix 2: List of Key Event Relationships in the AOP .....</b>   | <b>37</b> |
| List of Adjacent Key Event Relationships.....   | 37        |
| Relationship: 1508: Inhibition, Calcineurin Activity leads to Interference, nuclear localization of NFAT<br>( <a href="https://aopwiki.org/relationships/1508">https://aopwiki.org/relationships/1508</a> ) ..... | 37        |
| Evidence Supporting Applicability of this Relationship.....   | 38        |
| Key Event Relationship Description.....   | 38        |
| Evidence Supporting this KER.....   | 39        |
| Quantitative Understanding of the Linkage.....  | 40        |


|  |    |
|--|----|
| Relationship: 1017: Interference, nuclear localization of NFAT leads to Reduction, NFAT/AP-1 complex formation<br>( <a href="https://aopwiki.org/relationships/1017">https://aopwiki.org/relationships/1017</a> ) .....    | 42 |
| Evidence Supporting Applicability of this Relationship.....  | 43 |
| Key Event Relationship Description .....   | 43 |
| Evidence Supporting this KER.....  | 43 |
| Quantitative Understanding of the Linkage.....   | 44 |
| Relationship: 1509: Reduction, NFAT/AP-1 complex formation leads to Suppression, IL-2 and IL-4 production<br>( <a href="https://aopwiki.org/relationships/1509">https://aopwiki.org/relationships/1509</a> ) .....         | 46 |
| Evidence Supporting Applicability of this Relationship.....  | 46 |
| Key Event Relationship Description .....   | 46 |
| Evidence Supporting this KER.....  | 47 |
| Quantitative Understanding of the Linkage.....   | 49 |
| Relationship: 1510: Suppression, IL-2 and IL-4 production leads to Impairment, T-cell dependent antibody response<br>( <a href="https://aopwiki.org/relationships/1510">https://aopwiki.org/relationships/1510</a> ) ..... | 52 |
| Evidence Supporting Applicability of this Relationship.....  | 52 |
| Key Event Relationship Description .....   | 53 |
| Evidence Supporting this KER.....  | 53 |
| Quantitative Understanding of the Linkage.....   | 55 |

## Background

Although there are other stressors that inhibit CN activity, this AOP is mainly based on an understanding of immunosuppression caused by the complex of FK506 and FKBP12 and cyclophilin and CsA, on which a significant body of scientific literature has been published.

We look forward to future amendments to this AOP with up-to-date information on other stressors, which will more clarify the linkage between inhibition of CN activity and impairment of TDAR.

## Graphical Representation



## Summary of the AOP

### Events

Molecular Initiating Events (MIE), Key Events (KE), Adverse Outcomes (AO)

| Sequence | Type | Event ID | Title   | Short name                                     |
|----------|------|----------|---|--|
| 1        | MIE  | 980      | Inhibition, Calcineurin Activity<br>( <a href="https://aopwiki.org/events/980">https://aopwiki.org/events/980</a> )               | Inhibition, Calcineurin Activity               |
| 2        | KE   | 979      | Interference, nuclear localization of NFAT<br>( <a href="https://aopwiki.org/events/979">https://aopwiki.org/events/979</a> )     | Interference, nuclear localization of NFAT     |
| 3        | KE   | 981      | Reduction, NFAT/AP-1 complex formation<br>( <a href="https://aopwiki.org/events/981">https://aopwiki.org/events/981</a> )         | Reduction, NFAT/AP-1 complex formation         |
| 4        | KE   | 1202     | Suppression, IL-2 and IL-4 production<br>( <a href="https://aopwiki.org/events/1202">https://aopwiki.org/events/1202</a> )        | Suppression, IL-2 and IL-4 production          |
| 5        | AO   | 984      | Impairment, T-cell dependent antibody response<br>( <a href="https://aopwiki.org/events/984">https://aopwiki.org/events/984</a> ) | Impairment, T-cell dependent antibody response |



## Key Event Relationships

| Upstream Event  | Relationship Type | Downstream Event                               | Evidence | Quantitative Understanding |
|---|-------------------|--|----------|----------------------------|
| Inhibition, Calcineurin Activity<br>( <a href="https://aopwiki.org/relationships/1508">https://aopwiki.org/relationships/1508</a> )           | adjacent          | Interference, nuclear localization of NFAT     | Moderate | Moderate                   |
| Interference, nuclear localization of NFAT<br>( <a href="https://aopwiki.org/relationships/1017">https://aopwiki.org/relationships/1017</a> ) | adjacent          | Reduction, NFAT/AP-1 complex formation         | High     | High                       |
| Reduction, NFAT/AP-1 complex formation<br>( <a href="https://aopwiki.org/relationships/1509">https://aopwiki.org/relationships/1509</a> )     | adjacent          | Suppression, IL-2 and IL-4 production          | High     | High                       |
| Suppression, IL-2 and IL-4 production<br>( <a href="https://aopwiki.org/relationships/1510">https://aopwiki.org/relationships/1510</a> )      | adjacent          | Impairment, T-cell dependent antibody response | High     | High                       |

## Stressors

| Name                                  | Evidence |
|---------------------------------------|----------|
| Tacrolimus (also FK506)               | High     |
| Cyclosporin                           | High     |
| Pimecrolimus                          | High     |
| Gossypol                              | Moderate |
| Kaempferol                            | Moderate |
| Dodecylbenzene sulfonate              | Moderate |
| Dibefurin                             | Moderate |
| Ascomycin                             | Moderate |
| 1,5-dibenzoyloxymethyl-norcantharidin | Moderate |

## Overall Assessment of the AOP

Inhibition of CN might induce suppression of cytokines production from all the T helper cell subsets as well as other immune functions of other immune cells. Suppression of cell-mediated immunity is involved in the pharmacology of preventing hyper immune reactions such as rejection and GVHD, and treatment of autoimmune and allergic disorders such as psoriasis and atopic dermatitis. On the other hand, CN inhibition might induce immunosuppression-derived adverse outcomes. One of the effects is increased frequency and/or severity of infections. Compromised host might be related with impairment of multiple immune functions; however, impaired TDAR seems to be usually related. Moreover, TDAR is the frequently used measurable endpoint in immunotoxicity testing according the ICH S8 or US EPA OPPTS 870.7800 immunotoxicity testing guideline. Therefore, the present AOP focus on CN inhibition-induced impairment of TDAR.

When stressors bind to calcineurin-A (CnA) with immunophilin, CN phosphatase activity is inhibited. Immunophilins are composed of a family of highly conserved proteins that have the ability to bind immunosuppressive drugs. This interfere with the nuclear localization of NFAT, the substrate for CN. As a result, the formation of functional NFAT/ AP-1 complexes that bind at the site of IL-2, IL-4 and other cytokine promoters in each of the T helper cell subsets is reduced, thereby suppressing production of these cytokines. Among the affected cytokines TDAR is impaired mainly by the suppression of production of IL-2 and IL-4, which affect the proliferation and differentiation of B-cells to lower TDAR. We have identified a number of key events (KEs) along this pathway, and based on these key event relationships (KERs), created an AOP for inhibition of CN activity leading to impaired TDAR.

Since each KE involving MIE and AO is quantifiable, and shows similar dose responses with the CNIs in vitro, this AOP is useful for understanding immunosuppression due to inhibition of CN activity. In addition, each KER is based on sufficient scientific evidence and exhibits no contradiction with dose responses of adjacent KEs.

Since CN/NFAT system is conserved among vast variety of species and the function in immune system is common in at least human and mice, this AOP might be applicable to many mammalian species, including humans and rodents.

### Domain of Applicability

#### Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | Moderate |

#### Taxonomic Applicability

| Term                | Scientific Term     | Evidence | Links  |
|---------------------|---------------------|----------|--|
| Homo sapiens        | Homo sapiens        | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> )   |
| Mus musculus        | Mus musculus        | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090</a> ) |
| Macaca fascicularis | Macaca fascicularis | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9541">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9541</a> )   |
| Rattus norvegicus   | Rattus norvegicus   | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10116">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10116</a> ) |

## Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

The proposed AOP regarding inhibition of CN activity leading to impaired TDAR is not dependent on life stage, sex, or age. Since tacrolimus (FK506) ointment (Protopic) is approved for pediatric atopic dermatitis, the MOA for immunosuppression appears to be applicable to all life stages. The applicable state is considered supported by the draft FDA guidance for immunotoxicology that was recently issued (2020) indicating that “example of immunotoxicology testing could included TDAR assay” to address the concern of immunotoxicity in offspring in juvenile animal studies.

Since FK506 or CsA-induced outcomes in humans are mimicked by similar responses in a variety of animal models including non-human primates and rodents, immunosuppression induced by inhibition of CN activity is considered to occur across a variety of mammalian species.

In addition to the drugs, it is known that CN activity is suppressed by alkeylbenzene sulfonate (dodecylbenzene sulfonate) extracted from an acrylonitrile butadiene rubber (Ito et al. 2013), suggesting that the proposed AOP would be applicable to non-pharmacological agents.

For the chemicals such as pesticide, the TDAR assay is also recommended in the US EPA OPPTS 870.7800 immunotoxicity testing guideline.

## Essentiality of the Key Events

Essentiality is supported by several knockout animals as follows.

| Stage         | Essentiality   | Evidence | Supported by literatures   |
|---------------|----------------|----------|--|
| MIE and later | CnA-KO mice    | Strong   | The CN molecule consists of two regions, CnA and CnB, of which CnA exhibits phosphatase activity. In CnA-KO mice, T-cell proliferation in response to ovalbumin stimulation is lower than that for wild-type mice and is not complemented by normal antibody producing cells. In addition, when stimulated with ovalbumin, CnA-KO mice produce less IFN- $\gamma$ , IL 2, and IL 4 than wild-type mice. However, primary antibody response in CnA-KO mice is normal in response to TNP-ovalbumin, which means that CnA deficiency affects only T cell-dependent antibody response (TDAR) (Zhang et al. 1996).  |
| KE1 and later | NFAT-KO mice   | Strong   | The following phenotypes are observed in NFAT-KO mice: moderate hyperproliferation with splenomegaly, moderately enhanced B- and T-cell responses, with bias towards Th2-cell response, decreased IFN- $\gamma$ production in response to T-cell receptor (TCR) ligation, reduced proliferative responses by T cells, impaired repopulation of the thymus and lymphoid organs, impaired Th2- cell responses and IL-4 production, grossly impaired T-cell effector functions, profound defects in cytokine production and cytolytic activity, B-cell hyperactivity, impaired development of CD4 and CD8 single-positive cells, increased apoptosis of double-positive thymocytes, and mild hyperactivation of peripheral T cells.<br><br>Therefore, the study of NFAT-KO mice shows that NFAT is involved in a wide range of immune responses, and some of these phenomenon are known to be regulated by CN. Suppression of T-cell-derived cytokines is noted both in CnA-knockout and NFAT-knockout mice, which indicates that the production of T-cell derived cytokines such as IL-2 and IL-4 is regulated by the CN-NFAT system (Macian, 2005). |
| Stressor      | FKBP12-KO mice | Moderate | FK506 induces suppression of immune responses; however, there is no literature showing a relationship of a relationship between FKBP12 knockout and the immune system in the FKBP12-KO mouse model. Steric structure of FKBP12/FK506 complex is considered the key factor for inhibition of CN phosphatase activity, but not for the enzymatic activities of FKBP12.   |

### **Biological Plausibility**

T-cell functions are mainly regulated by the CN-NFAT system and suppression of CN activity in T cells is known to induce multiple types of immunosuppression, including T cell-dependent antibody response (TDAR).

Experiments with T cells indicate that TCR stimulation brings about increases in intracellular concentrations of  $\text{Ca}^{2+}$  that trigger CN activity, thereby inducing nuclear localization of substrate NFAT per dephosphorylation. The localized NFAT forms complexes with activator protein 1 (AP-1) at the promoter sites of the T cell cytokine genes and induces production of the cytokines.

CN phosphatase activity is known to be inhibited by the formation of immunophilin-CN inhibitor (CNI) complexes, such as CsA/cyclophilin complexes or FK506/FK506-binding protein (FKBP) 12 complexes. Immunophilins are a general class of proteins that exhibit peptidyl-propyl isomerase (PPIase) activity, but there is no similarity between amino-acid sequences of the two classes of immunophilins. The three-dimensional structures of immunophilin complexes are essential to the inhibition of CN phosphatase activity, even though their enzymatic activities are not.

It is also known that one of the effects on immune function when CNI forms complexes with its respective immunophilin and inhibits CN activity is the suppression of IL-2 and other T-cell derived cytokine production. It is further known that inhibition of CN leads to suppression of TDAR because IL 2 and IL 4 mainly promote the proliferation, class switching, differentiation, and maturation of B-cells.

Furthermore, CN-NFAT also exists in B cells and it has been reported that CNIs do suppress production of certain cytokines from them. At the time of our review of the literature, however, we did not find any reports of a direct effect of CN inhibition on B cells, such as changes in proliferation, class switching, differentiation, or maturation of B cells.

Also, although CN-NFAT is known to exist in dendritic cells, natural killer T (NKT) cells, and other types of cells in which it regulates the expression of IL-2 receptors, there are no reports of effects on the production of T cell-dependent antibodies due to CNI-induced alteration in expression of IL-2 receptors in these cells.

CN-NFAT system-mediated immunosuppression is well understood based on the pharmacology of some CNI drugs (mostly FK506 and Cs A); therefore, AOP of CN inhibition-induced suppression of TDAR is useful for prediction of CN-mediated immunotoxicity.

| KE R  | KEup-<br>KEdown  | Evidence | Rationales supported by literatures  |
|-------|--|----------|--|
| KER 1 | CN inhibition to interference, NFAT nuclear translocation                            | Moderate | <p>CN phosphatase activation through TCR stimulation dephosphorylates NFAT, thereby promoting nuclear localization of NFAT.</p> <p>CN phosphatase activity in T cells could be inhibited by CNI/immunophilin complexes, thus interfering with dephosphorylation and nuclear localization of NFAT.</p> <p>The known mechanisms for inhibition of CN phosphatase activity by FK506, CsA, or other CNIs are initiated by the formation of complexes with their respective immunophilin species. Immunophilins are general classes of proteins that exhibit PPlase activity, but modification of these functions is unrelated to inhibition of CN activity and thus thought to arise in the molecular structure of the complexes (Schreiber and Crabtree 1992, Liu et al. 1993, Bierer et al. 1993, Bram et al. 1993, Rao et al. 1997, Liu et al. 1991).</p>   |
| KER 2 | Interference, nuclear localization of NFAT to reduction, NFAT/AP-1 complex formation | Strong   | <p>CN activity dephosphorylates NFAT, thereby promoting its nuclear translocation. Nuclear-located NFAT binds with AP-1 at the promoter regions of the cytokine genes to promote T-cell cytokine production.</p> <p>Inhibition of dephosphorylation of NFAT by CNIs prevents nuclear export of NFAT and resultant binding with AP-1 at the promoter region of the T cell cytokine genes.</p> <p>NFAT has NLS and NES domains among and adjacent to the N-terminal region rich in SP motifs, and once the SP region is dephosphorylated, the NLS domain is exposed whereas the NES domain is covered, which leads to translocation of NFAT into the nucleus (Matsuda and Koyasu 2000).</p> <p>CNIs interference with the nuclear localization of NFAT in T cells leads to a reduction in the formation of NFAT/AP-1 complexes, thereby suppressing transcription of IL-2, IL-4, and a number of other cytokines (Maguire et al. 2013, Jain et al. 1992, Jain et al. 1993).</p>  |
| KER 3 | Reduction, NFAT/AP-1 complex formation to suppression of IL-2 and IL-4 production    | Strong   | <p>NFAT/AP-1 complexes bind to the promoter regions of the cytokine genes, which promotes production of cytokines in T cells. Of these cytokines, IL-2 and IL-4 have a major role in promoting proliferation, maturation and class-switching of B cells, and development of TDAR.</p> <p>Reduction of NFAT/AP-1 complex formation in the nucleus due to inhibition CN activity by CNIs suppresses production of T-cell derived cytokines, including IL-2 and IL-4.</p> <p>T-5224, a selective c-Fos/AP-1 inhibitor, inhibits the DNA-binding activity of AP-1 in primary murine T cells. T-5224 also inhibits CD25 (one of IL-2 receptors) up-regulation, IL-2 production, and c-Fos DNA-binding activity in mice (Yoshida et al. 2015).</p> <p>Dexamethasone represses the IL-2 mRNA induction. glucocorticoid-induced leucine zipper (GILZ) is one of the most prominent glucocorticoid-induced genes, and inhibited the induction of the NFAT reporter and interferes with the AP-1 component of the NFAT/AP-1 complex. GILZ also inhibits the IL-2 promoter (Mittelstadt et al. 2001).</p> <p>Ursolic acid suppressed activation of three immunoregulatory transcription factors NF-kB, NFAT and AP-1. Treatment of lymphocytes and CD4+ T cells with ursolic acid inhibited secretion of IL-2 and IL-4 cytokines. Treatment of CD4+ T cells with ursolic acid suppressed mRNA level of IL-2. Treatment of lymphocytes with ursolic acid inhibited the upregulation of CD25 expression on T cells (Checker et al. 2012).</p> |

|      |  |        |   |
|------|--|--------|---|
| KER4 | Suppression of IL-2 and IL-4 production to impaired TDAR | Strong | <p>T cell-derived cytokines play important roles in TDAR. Among them, IL-2 promotes proliferation of B cells, and IL-4 affects maturation and class switching of B cells as well as proliferation.</p> <p>Inhibition of CN activity by CNIs is known to suppress production of multiple cytokine species from T cells.</p> <p>Of these cytokines and receptors, suppression of IL-2 and IL-4 production mainly leads to impairment of TDAR.</p> <p>Suppressed production of other cytokines due to inhibition of CN activity exhibits only minor effects, if any, on TDAR.</p> <p>CsA is known to be one of the calcineurin inhibitors. CsA-treatment is reported to suppress the productions of IL-2 and IL-4 and result in reduced productions of antigen-specific IgM and IgG in cynomolgus monkeys (Gaida K. 2015).</p> <p>Dupilumab is known as anti-IL-4/13 receptor (IL-4/13R) antibody. Dupilumab (Dupixent) reduces productions of immunoglobulin (Ig) E and antigen specific IgG1 in mice (Sanofi K.K. 2018). It suggests that the blocking of IL-4 signaling by anti-IL-4/13R antibody results in the decrease in T cell dependent antibody production.</p> <p>Th2 cells produce cytokines including IL-4. Suplatast tosilate (IPD) is known as an inhibitor of the production of IL-4 and IL-5 in Th2 cells and reduces the production of antigen specific IgE in human cell culture and mice (Taiho Pharmaceutical 2013). These findings suggests that the reduction of IL-4 production by the inhibitor of Th2 cell cytokines results in reduced production of IgE and/or IgG1 through inhibitions of maturation, proliferation and class switching of B cells.</p> <p>IL-2 binds to IL-2 receptor (IL-2R) and acts on T cells. CD25 is one of the IL-2R. Basiliximab (Simulect) is known as anti-CD25 antibody. Basiliximab binds to IL-2R and blocks IL-2 signaling. Clinical transplantation study of basiliximab reveals decreases in rejections. On the other hand, basiliximab inhibits the activation of antigen specific T cells (Novartis Pharma 2016).</p> <p>FK506 and CsA suppress mRNA expression levels of cytokines in T cells including IL-2 and IL-4 that stimulate proliferation of B cells as well as B cell activation and class switching (Heidt et al, 2010).</p> |
|------|--|--------|---|

## Empirical Support

| KE R | KEup-<br>KEdown  | Evidence | Empirical support of KERs  |
|------|--|----------|--|
|      |  |          | CN phosphatase activity is inhibited with IC50 values of 0.5 nM (FK506) and 5nM (CsA) after 1 hours treatment (Fruman et al.1992).   |
| KER1 | Inhibition, calcineurin activity leadsto interference , nuclear localization of NFAT | Moderate | <p>Concentration-dependent reduction of in vitro nuclear localization of NFAT was evident at concentrations from 0.1 nM (Jurkat T cells) or 10nM (human CD4+ T cells) and up to 1 <math>\mu</math>M (1000 nM) under the conditions of 2 hours treatment of tacrolimus (Maguire et al. 2013).</p> <p>Interference with translocation of NFAT to the nucleus is also detected using gel mobility shift assay to test nuclear extracts and cytoplasmic extracts, in which the examined concentration of FK506 was 10ng/mL (Flanagan et al. 1991).</p> |
|      |  |          | CN phosphatase activity and nuclear translocation of NFAT seems to be suppressed by CNIs at the similar ranges of doses and reaction times of 1 to 2 hours.  |

|      |  |          |  |
|------|--|----------|--|
| KER2 | Interference, nuclear localization of NFAT leads to reduction, NFAT/AP-1 complex formation | Strong   | <p>Concentration-dependent reduction of in vitro nuclear localization of NFAT was evident at the concentration from 0.1 nM (Jurkat T cells) or 10nM (human CD4+ T cells) and up to 1 <math>\mu</math>M (1000 nM) under the conditions of 2 hours treatment (Maguire et al. 2013)</p> <p>Treatment of activated T cells with FK506 at 100ng/mL (124nM) or CsA at 500ng/mL (416nM) for 2 hours hinders the formation of functional NFAT/AP-1 in the nucleus (Flanagan et al. 1991).</p> <p>Gel mobility shift assays using Ar-5 human T cells stimulated with cross-linked anti-CD3 antibody showed that NFAT/AP-1 (cFos and Jun) complexes were found only in the nuclear extract with preexisting NFAT in the cytoplasm after T cell stimulation and that the NFAT/AP-1 complexes in the nucleus decreased after 2 hours treatment with CsA at 1<math>\mu</math>M (Jain et al. 1992).</p> <p>Decreased NFAT translocated to the nucleus, induced by FK506 at 100ng/mL (124nM) or CsA at 500ng/mL (416nM) after 2 hours treatment, hinders the formation of the functional NFAT/AP-1 complexes necessary to bind IL-2 promoters (Flanagan et al. 1991).</p> <p>NFAT/AP-1 complex formation was also reported to be inhibited by CNI (Rao et al. 1997).</p> <p>Quantitative data on NFAT/AP-1 complex formation in the nucleus is insufficient; however, inhibition of nuclear localization of NFAT and following NFAT/AP-1 complex formation in the nucleus are simultaneously detected by gel mobility shift assays at the concentration of FK506 within the range for inhibition of nuclear translocation of NFAT using imaging flowcytometry after 2 hours culture of T cells.</p> |
|      |  | Moderate | <p>In NFATp- and NFAT4-deficient mice, cultured splenocytes bound anti-CD3 for 48 h indicates decreased production of Th1 cytokine including IL-2 (Ranger et al. 1998).</p> <p>In purified T cells from male C57BL/6J mice, T-5224 (a selective c-Fos/AP-1 inhibitor) inhibits the DNA-binding activity of AP-1 and CD25 (one of IL-2 receptors) up-regulation at 80 <math>\mu</math>g/mL, and IL-2 production in a dose-dependent manner from 40 to 80 <math>\mu</math>g/mL (Yoshida et al. 2015).</p> <p>In splenic lymphocytes stimulated with concanavalin A for 24 h in C57BL/6 mice, ursolic acid suppressed products of NF-kB, NFAT and AP-1 at 5 <math>\mu</math>M for 4 h. Secretion of IL-2 and IL-4 was inhibited in lymphocytes stimulated with concanavalin A for 24 h at concentrations of 0.5, 1 and 5 <math>\mu</math>M of ursolic acid, and lymphocytes and CD4+ T cells stimulated with anti-CD3/anti-CD28 mAb for 24 h at concentration of 5 <math>\mu</math>M of ursolic acid. In CD4+ T cells stimulated with anti-CD3/anti-CD28 mAb for 24 h, ursolic acid suppressed mRNA level of IL-2 at 5 <math>\mu</math>M for 4 h. In lymphocytes stimulated with concanavalin A for 24 h, ursolic acid inhibited CD25 expression at 5 <math>\mu</math>M for 4 h (Checker et al. 2012).</p> <p>Gel mobility shift assay revealed that treatment of activated T cells with FK506 at 100ng/mL (124nM) or CsA at 500ng/mL (416nM) for 2 hours hinders NFAT nuclear translocation and following formation of NFAT/AP-1 complexes in the nucleus (Flanagan et al. 1991).</p>  |
| KER  | Reduction, NFAT/AP-1   |          | <p>Preceding NFAT nuclear localization after T cell activation is suppressed with FK506 at the dose range of 0.01nM (Jurkat T cells) or 10nM (CD4+ T cells) to 1<math>\mu</math>M (Maguire et al. 2013), and NFAT nuclear localization and NFAT/AP-1 complex formation is shown to be strongly related (Jain et al. 1992, Jain et al. 1993).</p> <p>In CD3/PMA-activated human T cells, FK506 suppressed production of IL-2, IL-4, and IFN-<math>\gamma</math> at the concentrations of 1.2 to 12.5 nM after 22 to 24 hours culture as well as inhibited expression of IL-2, IL-4, and IFN-<math>\gamma</math> mRNA at 10 nM (Dumont et al. 1998).</p>   |

|   |  |  |
|---|--|--|
| 3 | complex formation leads to suppression, IL-2 and IL-4 production | <p>Treatment with CsA completely eliminated detectable IL-2 release from 3A9 T cells co-cultured with antigen-bearing Ch27 B cells with an IC25 and IC50 for IL-2 production of 1.19 nM and 1.99 nM. Treatment with other immunosuppressant compounds (dexamethasone, azathioprine, methotrexate, benzo(a)pyrene and urethane) also resulted in decreased IL-2 release from stimulated 3A9 T cells at non-cytotoxic concentrations. Urethane, a weakly immunosuppressive chemical, was least potent in the assay, with an IC25 and IC50 for IL-2 secretion of 4.24 mM and 13.26 mM (D.M. Lehmann. et al. 2018).</p> <p>In female B6C3F1 mice, 1,2:5,6-dibenzanthracene exposure reduced production of IL-2 in spleen cell culture supernatants after in vitro stimulation with Concanavalin A or lipopolysaccharide (Donna, C. et al. 2010).</p> <p>Treatment with CsA at 50 mg/kg BID via oral gavage or 2C1.1 (a fully human anti-ORAI1 monoclonal antibody) at 25 mg/kg single IV resulted in reduction of IL-2, IL-4, IL-5, and IL-17 cytokine production from PMA/ionomycin stimulation of whole blood in the cynomolgus monkey (Kevin, G. et al. 2014).</p> <p>In male CD-1 mice, chronic psychosocial stress (types of social outcome occurred: residents becoming subordinates) reduced IL-2 release in response to keyhole limpet hemocyanine (Alessandro, B. et al. 2003).</p> <p>Therefore, concentration of CNI needed for inhibition of NFAT/AP-1 complex formation in the nucleus is higher than that for inhibition of IL-2 and IL-4 production. A time lag is found between the two KEs; 2 hours for KE2 and 22 to 48 hours for KE3.</p> |
|---|--|--|



|      |   |        |   |
|------|---|--------|---|
| KER4 | Suppression, IL-2 and IL-4 production leads to Impairment, T-cell dependent antibody response | Strong | <p>Cynomolgus monkeys treated with CsA at 50 mg/kg BID for 24 days suppression of IL-2, IL-4 and sheep red blood cell (SRBC)-specific IgM and IgG (Gaida K. 2015).</p> <p>In the allergen-induced pneumonia model in mice, dupilumab (anti-IL-4/13R antibody) reduced productions of IgE and antigen specific IgG1 at 25 mg/kg of twice weekly subcutaneous administration for 4 weeks (Sanofi K.K. 2018).</p> <p>In mice immunized with dinitrophenyl antigen by i.p. injection, suplatast tosilate (an inhibitor of the production of cytokines such as IL-4 and IL-5 on Th2 cell) reduced productions of antigen specific IgE at 10, 20, 50 and 100 mg/kg of oral administration for 5 days (Taiho Pharmaceutical 2013). In human cell culture immunized with Japanese cedar antigen, suplatast tosilate reduced productions of antigen specific IgE at the concentration of 10 µg/mL for 10 days (Taiho Pharmaceutical 2013).</p> <p>1,2:5,6-dibenzanthracene single administration suppressed production of IL-2 and total IgG antibody in mice at the dose levels of 3 and 30 mg/kg (Donna, C. et al. 2010).</p> <p>In male CD-1 mice, chronic psychosocial stress (types of social outcome occurred: residents becoming subordinates) for 21 days reduced IL-2 release in response to KLH (keyhole limpet hemocyanine) and decrease in anti-KLH IgG (Alessandro, B. et al. 2003). FK506 or CsA suppressed production of IL-2 in mouse mixed lymphocyte reaction (MLR) at 0.1 to 10 nM of FK506 and 10 to 100 nM of CsA as well as in human MLR at 0.1 to 10 nM of FK506 and 10 to 100 nM of CsA (Kino et al. 1987a).</p> <p>In CD3/phorbol 12-myristate-13-acetate-activated human T cells, FK506 suppressed production of IL-2, IL-4 and Interferon (IFN)-γ at the concentrations of 1.2 to 12.5 nM as well as inhibited expression of IL-2, IL-4 and IFN-γ mRNA at the concentrations of 10 nM. (Dumont et al. 1998).</p> <p>Rats were treated with FK506 for over four weeks and immunized with keyhole limpet hemocyanine (KLH), after which serum concentration of anti-KLH IgM and IgG reduced at the dose levels of 3 mg/kg/day (Ulrich et al. 2004).</p> <p>Mice were treated with FK506 or CsA for 4 days, and immunized with sheep red blood cells (SRBC), after which antigen-specific plaque-forming splenocytes were reduced at dose levels of 3.2, 10, 32 and 100 mg/kg of FK506 or 32 and 100 mg/kg of CsA (Kino et al. 1987b).</p> <p>After 9-day culture of B cells and non-pre-activated T cell stimulation with FK506 or CsA, the levels of IgM and IgG in the culture supernatant were reduced at 0.3 and 1.0 ng/mL (0.37 and 1.24 nM) of FK506 or 50 and 100 ng/mL (41 and 83nM) of CsA (Heidt et al, 2010).</p> <p>After 4-day culture of SKW6.4 cells (IL-6-dependent IgM-secreting human B-cell line) and anti-CD3/CD28 stimulated PBMC culture supernatant with FK506 or CsA, the level of IgM in the culture supernatant was reduced at the concentrations of 0.01 to 100 ng/mL (0.01 to 124 nM) of FK506 or 0.1 to 1000 ng/mL (0.08 to 832 nM) of CsA (Sakuma et al, 2001).</p> <p>In vitro suppression of T-cell-derived cytokines and T-cell-dependent antibody production or antibody production after polyclonal T-cell stimulation showed similar dose responses to CNIs. Time gaps were found, however, between these two events, which showed earlier onset of cytokine production and delayed onset of antibody production.</p> |
|------|---|--------|---|

Based on these findings of empirical support, each KE involving MIE and AO except for KE2 shows similar dose responses to the CNIs in vitro; however, culture time lag is noted, in that, 1 hour for MIE, 2 hours for KE1 and KE2, 22 to 24 hours for KE3 and more than days for AO.

## Quantitative Understanding

### KER1

No literature is available showing a clear quantitative relationship between the inhibition of CN phosphatase activity and nuclear translocation of NFAT; however, the dose responses of CN phosphatase activity and nuclear translocation of NFAT to CNI seem to be the same.

### KER2:

Gel mobility shift assay of activated T cells showed that NFAT/AP-1 complexes are only found in nuclear extract, which indicates a strong relationship between the nuclear translocation of NFAT and simultaneous complex formation with AP-1 in the nucleus. CNI treatment clearly suppresses the complex formation of nuclear located NFAT and AP-1 in the nucleus, which also shows the solid relationship between these adjacent two KEs although quantitative data on suppressed NFAT/AP-1 complex formation is insufficient (Flagan W.M. et al. 1991).

### KER3:

The quantitative relationship between the decreased formation of NFAT/AP-1 complexes and the production of IL2/IL-4 formation induced by CNIs has not been reported.

However, as mentioned in the empirical support, nuclear localization of NFAT is strongly related to NFAT/AP-1 complex formation in the nucleus based on the fact that these two events are detected simultaneously by gel mobility shift assay, and the dose responses of IL2/IL-4 production and nuclear translocation of NFAT inhibited by CNI are similar; therefore, dose ranges of CNI in the inhibitions of IL2/IL-4 production and NFAT/AP-1 complex formation in the nucleus might also be the same.

In addition, T-5224 and ursolic acid inhibit AP-1 DNA binding activity or production of NF- $\kappa$ B, NFAT and AP-1, respectively, and both suppress the IL-2 and/or IL-4 production with dose dependent manner including the doses of inhibiting NFAT-AP-1 system (Yoshida et al. 2015, Checker et al. 2012).

### KER4:

Cynomolgus monkeys treated with CsA at 50 mg/kg BID for 24 days suppression of IL-2, IL-4 and sheep red blood cell (SRBC)-specific IgM and IgG (Gaida K. 2015).

Inhibition of IL-4 production in mice treated with oral administration of suplatast tosilate suppresses antigen-specific IgE production in a dose-dependent manner (Taiho Pharmaceutical 2013). In the inhibition of IL-4 production in human cell culture by suplatast tosilate at the concentration of 10  $\mu$ g/mL for 10 days, antigen specific IgE production was suppressed from 56 to 72% and IL-4 production was suppressed from 58 to 76% (Taiho Pharmaceutical 2013).

As for IL-2 and antibody production, in vitro T-cell-induced polyclonal B cell activation to produce antibody was inhibited with anti-IL-2 and anti-IL-2R antibodies (Owens T, 1991).

In the human T-B cell co-culture stimulated with anti-CD3 monoclonal antibody, CNIs of FK506 and CsA lowered the levels of T-cell cytokines including IL-2 and IL-4 and inhibited IgM and IgG productions with a dose-dependent manner (Heidt S. 2010).

These results show the quantitative relationships between the inhibition of IL-4 or IL-2 by specific antibodies or CNI and suppression of antibody production.

## Considerations for Potential Applications of the AOP (optional)

The ICH S8 guideline, which covers immunosuppression of small molecule drugs, determines the need for immunotoxicity studies by comprehensively evaluating the findings of pharmacology, changes in the immune system in repeated-dose toxicity studies, and other factors using a Weight of Evidence approach. If there is concern about immunotoxicity, the presence or absence of immunotoxicity should be determined using an in vivo test system capable of assessing the functional changes of predicted immunotoxic target cells. If immunotoxicity is observed, additional studies including in vitro assays or clinical evaluation should be considered to assess the risk of immunotoxicity in humans. Because TDAR involves many immune cell populations, including T cells, B cells, and antigen-presenting cells, evaluation of TDAR is recommended when there is concern about immunotoxicity but the immunotoxic target cells are unclear. The S8 guidelines list KLH, SRBC, and tetanus toxin as antigens for TDAR.

The draft FDA immunotoxicity testing guidance (2020) covers immunosuppressive and immunostimulatory drugs and biologics; evaluating immunosuppressive drugs in the draft FDA guidance is similar to that in the S8 guideline, with in vivo TDAR assays recommended when toxic target cells are unknown. The draft guidance states that TDAR assays using KLH as an antigen have been established in mice, rats, dogs, minipigs, and cynomolgus monkeys, but the use of SRBC and tetanus toxin as antigens is also acceptable.

For the assessment for pesticides, US EPA OPPTS 870.7800 immunotoxicity testing guideline recommends TDAR using SRBC. The REACH guideline does not provide for immunotoxicity testing, but it provides triggers for conducting immunotoxicity testing.

The WHO/IPSS Immunotoxicity Risk assessment Guidance (2012) describes a strategy for assessing five categories of immunotoxicity risks, including immunosuppression. For risk assessment of immunosuppression, it calls for identification of immunosuppression risks, prediction of pathogenesis that may occur, and consideration of safety margins based on the WoE approach from human findings, infection resistance tests, immune function tests, general immune system assays, histopathological findings and organ weights in general toxicity studies, and hematological data.

The evaluation of immunotoxicity in F1 animals in the OECD Guidelines for Extended First Generation Reproductive and Developmental Toxicity Studies (TG443) requires that PFC and ELSA assays to measure primary IgM antibody production by TDAR using T-cell dependent antigens (SRBC, KLH, etc.) be performed. Furthermore, if changes are observed, the significance of the changes should be examined by comprehensively evaluating other data.

The outcomes of immunosuppression are susceptibility to infection and tumorigenesis, and the FDA guidance requires that immunosuppressive drugs be evaluated for carcinogenic risk using WoE approach based on the results of carcinogenicity and immunotoxicity studies. Meanwhile, the ICH S1B(R1) Draft Step 2 Guidelines for Carcinogenicity Testing calls for evaluation of carcinogenicity by WoE approach instead of rat carcinogenicity testing, because rodent carcinogenicity test models are less capable of detecting carcinogenicity. On the other hand, it is difficult to define susceptibility to infection as a measurable AO with a clear mechanism, because immune responses vary among pathogens. In fact, many immunotoxicity guidelines require that the risk of immunotoxicity be identified and assessed by evaluating immune functions.

In AOP154, it was difficult to define susceptibility to infection as an AO for the AOP154, so TDAR, which is recommended as an indicator of immunosuppression in many guidelines, was used as an AO. It is expected that several AOPs with TDARs as AOs will be developed, and based on these AOPs, it may be possible to develop an IATA to assess the risk of immunotoxicity characterized by TDARs.

## References

- Alessiani, M., Kusne, S., Martin, M., Jain, A., Abu-Elmagd, K., Moser, J., Todo, S., Fung, J. and Starzl, T. (1991). *Transplantation proceedings* 23 (1 Pt 2): 1501-3.
- Alessandro B, Paola S, Alberto E. Paneraic, Tiziana P, Paola Palanzaa and Stefano P (2003). *Journal of Neuroimmunology* 141: 58-64
- Antiga, E., Volpi, W., Torchia, D., Fabbri, P. and Caproni, M. (2011). *Clinical and experimental dermatology* 36 (3): 235-41.
- Beals, C.R., Clipstone, N.A., Ho, S.N. and Crabtree, G.R. (1997). *Genes & development* 11 (7): 824-34.
- Bhattacharyya, S., Deb, J., Patra, A.K., Thuy Pham, D.A., Chen, W., Vaeth, M., Berberich-Siebelt, F., Klein-Hessling, S., Lamperti, E.D., Reifenberg, K., Jellusova, J., Schweizer, A., Nitschke, L., Leich, E., Rosenwald, A., Brunner, C., Engelmann, S., Bommhardt, U., Avots, A., Müller, M.R., Kondo, E. and Serfling, E. (2011). *The Journal of experimental medicine* 208 (4): 823-39.
- Bierer, B.E., Holländer, G., Fruman, D. and Burakoff, S.J. (1993). *Current opinion in immunology* 5 (5): 763-73.
- Boussiotis, V.A., Nadler, L.M., Strominger, J.L. and Goldfeld, A.E. (1994). *Proceedings of the National Academy of Sciences of the United States of America* 91 (15): 7007-11.
- Bram, R.J., Hung, D.T., Martin, P.K., Schreiber, S.L. and Crabtree, G.R. (1993). *Molecular and cellular biology* 13 (8): 4760-9.
- Cameron, A.M., Nucifora, F.C. Jr., Fung, E.T., Livingston, D.J., Aldape, R.A., Ross, C.A. and Snyder, S.H. (1997). *The Journal of biological chemistry* 272 (44): 27582-8.
- Checker, R., Sandur, SK., Sharma, D., Patwardhan, RS., Jayakumar, S., Kohli, V., Sethi, G., Aggarwal, BB. and Sainis, KB. (2012). *PLoS One*. 7(2): e31318.
- Chung, B.H., Kim, K.W., Yu, J.H., Kim, B.M., Choi, B.S., Park, C.W., Kim, Y.S., Cho, M.L. and Yang, C.W. (2014). *Transplant immunology* 30 (4): 159-67.
- Cohan, V.L., Undem, B.J., Fox, C.C., Adkinson, N.F. Jr., Lichtenstein, L.M. and Schleimer, R.P. (1989). *The American review of respiratory disease* 140 (4): 951-4.
- Conboy, I.M., Manoli, D., Mhaikar, V., and Jones, P.P. (1999). *Proceedings of the National Academy of Sciences of the United States of America* 96 (11): 6324-9.
- Donna C. S, Matthew J. S and Kimber L. W Jr. (2010). *Journal of Immunotoxicology*, 7:3, 219-231
- Dumont, F.J., Staruch, M.J., Fischer, P., DaSilva, C. and Camacho, R. (1998). *Journal of immunology* 160 (6): 2579-89.
- Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, S., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J.M., Frei, U., Vanrenterghem, Y., Daloze, P. and Halloran, P.F.; ELITE-Symphony Study. (2007). *The New England journal of medicine* 357 (25): 2562-75.
- Ekberg, H., Bernasconi, C., Tedesco-Silva, H., Vítko, S., Hugo, C., Demirbas, A., Acevedo, R.R., Grinyó, J., Frei, U., Vanrenterghem, Y., Daloze, P. and Halloran, P. (2009). *American journal of transplantation* 9 (8): 1876-85.
- Flanagan, W.M., Corthésy, B., Bram, R.J. and Crabtree, G.R. (1991). *Nature* 352 (6338): 803-7.
- Foletta, V.C., Segal, D.H. and Cohen, D.R. (1998). *Journal of leukocyte biology* 63 (2): 139-52.
- Fruman, D. A., Klee, C. B., Bierer, B. E. and Burakoff, S. J. (1992). *Proceedings of the National Academy of Sciences of the United States of America*. 89(9):3686-90.
- Fruman, D.A., Bierer, B.E., Benes, J.E., Burakoff, S.J., Austen, K.F. and Katz, H.R. (1995). *Journal of immunology* 154 (4): 1846-51.

- Fung, J., Abu-Elmagd, K., Jain, A., Gordon, R., Tzakis, A., Todo, S., Takaya, S., Alessiani, M., Demetris, A., Bronster, O., Martin, M., Miele, L., Selby, R., Reyes, J., Doyle, H., Stieber, A., Casavilla, A. and Starzl, T. (1991). *Transplantation proceedings* 23 (6): 2977-83.
- Gaida K., Salimi-Moosavi H., Subramanian R., Almon V., Knize A., Zhang M., Lin F.F., Nguyen H.Q., Zhou L., Sullivan J.K., Wong M., McBride H.J. (2015). *J Immunotoxicol* 12:164-173.
- Glynne, R., Akkaraju, S., Healy, J.I., Rayner, J., Goodnow, C.C. and Mack, D.H. (2000). *Nature* 403 (6770): 672-6.
- Goldfeld, A.E., Flemington, E.K., Boussiotis, V.A., Theodos, C.M., Titus, R.G., Strominger, J.L. and Speck, S.H. (1992). *Proceedings of the National Academy of Sciences of the United States of America* 89 (24): 12198-201.
- Goldfeld, A. E., Tsai, E., Kincaid, R., Belshaw, P. J., Schrieber, S. L., Strominger, J. L. and Rao, A. (1994). *Journal of experimental medicine*. 180(2): 763-768.
- Heidt, S., Roelen, D. L., Eijnsink, C., Eikmans, M., van Kooten, C., Claas, F. H. and Mulder, A. (2010). *Clinical and experimental immunology*. 159(2): 199-207.
- Hiroi, J., Sengoku, T., Morita, K., Kishi, S., Sato, S., Ogawa, T., Tsudzuki, M., Matsuda, H., Wada, A. and Esaki, K. (1998). *Japanese journal of pharmacology*. 76(2): 175-183.
- Hultsch, T., Albers, M. W., Schreiber, S.L. and Hohman, R. J. (1991). *Proceedings of the national academic science of the United States of America*. 14: 6229-6233.
- Imai, A., Sahara, H., Tamura, Y., Jimbow, K., Saito, T., Ezoe, K., Yotsuyanagi, T. and Sato, N. (2007). *European journal of immunology*. 37(7): 1730-1738.
- Ito N., Shibuguchi N., Ishikawa R., Tanaka S., Tokita Y., Nakajima-Shimada J., Hosaka K. (2013). *Biosci Biotechnol Biochem*. 77(5): 954-960
- Jain, J., McCaffrey, P. G., Valge-Archer, V. E. and Rao, A. (1992). *Nature*. 356(6372): 801-804.
- Jain, J., Miner, Z. and Rao, A. (1993). *Journal of immunology*. 151(2): 837-848.
- Jennings, C., Kusler, B. and Jones, P. P. (2009). *Innate immunity*. 15(2): 109-120.
- Kang, Y. J., Kusler, B., Otsuka, M., Hughes, M., Suzuki, N., Suzuki, S., Yeh, W. C., Akira, S., Han, J. and Jones, P. P. (2007). *Journal of immunology*. 179(7): 4598-4607.
- Kang, C. B., Hong, Y., Dhe-Paganon, S. and Yoon, H. S. (2008). *Neurosignals*. 16: 318-325.
- Kevin G, Hossein S, Raju S, Valerie A, Anna K, Ming Z, Fen-Fen L, Hung Q. N, Lei Z, John K. S, Min W and Helen J. M(2015). *Journal of Immunotoxicology*, 12:2, 164-173,
- Kim, T., Kim, N. and Kang, H. J. (2010). *Journal of leukocyte biology*. 88:1089-1097.
- Kino, T., Hatanaka, H., Miyata, S., Inamura, N., Nishiyama, M., Yajima, T., Goto, T., Okuhara, M., Kohsaka, M. and Aoki, H. (1987a). *Journal of antibiotics*. 40(9): 1256-1265.
- Kino, T., Hatanaka, H., Hashimoto, M., Nishiyama, M., Goto, T., Okuhara, M., Kohsaka, M., Aoki, H. and Imanaka, H. (1987b). *Journal of antibiotics*. 40(9): 1249-1255.
- Klee, C. B., Draetta, G. F. and Hubbard, M. J. (1988). *Advances in enzymology and related areas of molecular biology*. 61:149-200.
- Lee, Y. R., Yang, I. H., Lee, Y. H., Im, S. A., Song, S., Li, H., Han, K., Kim, K., Eo, S. K. and Lee, C. K. (2005). *Blood*. 105(10): 3951-3955.
- Lehmann, D.M., Williams, W.C. (2018). *Toxicol In Vitro*.53: 20–28.
- Liu, J., Farmer, J. D. Jr., Lane, W. S., Friedman, J., Weissman, I., and Schreiber, S. L. (1991). *Cell*. 66(4): 807-815.

- Liu, J., Albers, M. W., Wandless, T. J., Luan, S., Alberg, D. G., Belshaw, P. J., Cohen, P., MacKintosh, C., Klee, C. B. and Schreiber, S.L.. (1992). *Biochemistry*. 31(16):3896-901.
- Liu, J. (1993). *Immunology today*. 14(6): 290-305.
- Luster, M.I., and Rosenthal, G.J. (1993). *Environmental Health Perspectives*. 100: 219-36.
- Macian, F. (2005). *Nature reviews. Immunology*. 5(6): 472-84.
- Magari, K., Miyata, S., Ohkubo, Y., Mutoh, S. and Goto, T. (2003). *British journal of pharmacology*. 139: 927-934.
- Maguire O, Tornatore KM, O'Loughlin KL, Venuto RC and Minderman H. (2013). *Cytometry A*. 83(12):1096-104.
- Matsuda, S., Koyasu, S. (2000). *Tanpakushitsu kakusan koso*. 45(11): 1823-1831.
- Meingassner, J.G. and Stütz, A. (1992). *Journal of investigative dermatology* 98(6): 851-5
- Mittelstadt, PR. and Ashwell, JD. (2001). *J Biol Chem*. 276(31):29603-10.
- Nalesnik, MA., Todo, S., Murase, N., Gryzan, S., Lee, PH., Makowka, L., and Starzl, TE. (1987). *Transplantation Proceedings* 19(5 Suppl 6): 89-92.
- Panhans-Gross, A., Novak, N., Kraft, S., and Bieber, T. (2001). *Journal of Allergy and Clinical Immunology* 107(2): 345-52.
- Pirsch, JD., Miller, J., Deierhoi, MH., Vincenti, F., and Filo, RS. (1997). *Transplantation* 63(7): 977-83.
- Ranger, AM., Oukka, M., Rengarajan, J. and Glimcher, LH. (1998). *Immunity*. 9(5):627-35.
- Rao, A., Luo, C., and Hogan, PG. (1997). *Annual Review of Immunology* 15: 707-47.
- Roman D., Ulrich P., Paul G., Court P., Vit P., Kehren., Mahl A., (2004). *Toxicology Letters* 149: 133-140.
- Sakuma, S., Kato, Y., Nishigaki, F., Sasakawa, T., Magari, K., Miyata, S., Ohkubo, Y., and Goto, T. (2000). *British Journal of Pharmacology* 130(7): 1655-63.
- Sakuma, S., Higashi, Y., Sato, N., Sasakawa, T., Sengoku, T., Ohkubo, Y., Amaya, T., and Goto, T. (2001a). *International Immunopharmacology* 1(6): 1219-26.
- Sakuma, S., Kato, Y., Nishigaki, F., Magari, K., Miyata, S., Ohkubo, Y., and Goto, T. (2001b). *International Immunopharmacology* 1(4): 749-57.
- Sasakawa, Y., Sakuma, S., Higashi, Y., Sasakawa, T., Amaya, T., and Goto, T. (2000). *European Journal of Pharmacology* 403(3): 281-8.
- Sasaki, T., Nakamura, W., Inokuma, S., and Matsubara, E. (2015). *Journal of Clinical Rheumatology* Feb 3.
- Schreiber, SL., and Crabtree, GR. (1992). *Immunology Today* 13(4): 136-42.
- Serfling, E., Berberich-Siebelt, F., Chuvpilo, S., Jankevics, E., Klein-Hessling, S., Twardzik, T., and Avots, A., (2000). *Biochimica et Biophysica Acta* 1498 (1): 1-18.
- Sieber M., Baumgrass R., (2009). *Cell Commun Signal* Oct 27;7:25
- Siekierka, JJ., Hung, SH., Poe, M., Lin, CS., and Sigal, NH. (1989a). *Nature* 341(6244): 755-57.
- Siekierka, JJ., Staruch, MJ., Hung, SH., and Sigal, NH. (1989b). *Journal of immunology* 143(5): 1580-3.
- Siekierka, JJ., Wiederrecht, G., Greulich, H., Boulton, D., Hung, SH., Cryan, J., Hodges, PJ., and Sigal, NH. (1990). *Journal of Biological Chemistry* 265(34): 21011-5.
- Sonoda, T., Takahara, S., Takahashi, K., Uchida, K., Ohshima, S., Toma, H., Tanabe, K., Yoshimura, N.; Japanese Tacrolimus Study Group. (2003). *Transplantation* 75(2): 199-204.
- Standaert, RF., Galat, A., Verdine, GL., and Schreiber, SL. (1990). *Nature* 346(6285): 671-4.

- Tamura, F., Masuhara, A., Sakaida, I., Fukumoto, E., Nakamura, T., and Okita, K. (1998). *Journal of Gastroenterology and Hepatology* 13(7): 703-8.
- Ulrich, P., Paul, G., Perentes, E., Mahl, A., and Roman D. (2004). *Toxicology Letters* 149(1-3): 123-31.
- Vacher-Coponat, H., Brunet, C., Moal, V., Loundou, A., Bonnet, E., Lyonnet, L., Ravet, S., Sampol-Manos, E., Sampol, J., Berland, Y., George, F.D., and Paul, P. (2006). *Transplantation* 82(4): 558-66.
- Vandewalle, A., Tourneur, E., Bens, M., Chassin, C., and Werts, C. (2014). *Cell Communication and Signaling* 12: 8
- Weiwad, M., Edlich, F., Kilka, S., Erdmann, F., Jarczowski, F., Dorn, M., Moutty, M.C. and Fischer, G. (2006). *Biochemistry* 45(51): 15776-84.
- Wicker, L.S., Boltz, R.C. Jr., Matt, V., Nichols, E.A., Peterson, L.B. and Sigal, N.H. (1990). *European journal of immunology* 20(10): 2277-83.
- Yoshida, T., Yamashita, K., Watanabe, M., Koshizuka, Y., Kuraya, D., Ogura, M., Asahi, Y., Ono, H., Emoto, S., Mizukami, T., Kobayashi, N., Shibasaki, S., Tomaru, U., Kamachi, H., Matsushita, M., Shiozawa, S., Hirono, S. and Todo, S. (2015). *Am J Transplant.* 15(10): 2565-75.
- Yoshimura, N., Matsui, S., Hamashima, T. and Oka, T. (1989). *Transplantation* 47(2): 356-9.
- Yoshino, T., Nakase, H., Honzawa, Y., Matsumura, K., Yamamoto, S., Takeda, Y., Ueno, S., Uza, N., Masuda, S., Inui, K. and Chiba, T. (2010). *Inflammatory bowel disease.* 16(12): 2022-33
- Zhang, B.W., Zimmer, G., Chen, J., Ladd, D., Li, E., Alt, F.W., Wiederrecht, G., Cryan, J., O'Neill, E.A., Seidman, C.E., Abbas, A.K. and Seidman, J.G.. (1996). *Journal of experimental medicine* 183(2): 413-20.
- Zhu, J. and McKeon, F. (1999). *Nature.* 398(6724): 256-60.
- de Paulis, A., Cirillo, R., Ciccarelli, A., de Crescenzo, G., Oriente, A. and Marone, G. (1991). *Journal of immunology* 147(12): 4278-85.
- de Paulis, A., Stellato, C., Cirillo, R., Ciccarelli, A., Oriente, A. and Marone, G. (1992). *Journal of investigative dermatology* 99(6): 723-8.
- van Dieren, J.M., Lambers, M.E.H., Kuipers, E.J., Samsom, J.N., van der Woude, C.J. and Nieuwenhuis, E.E.S. (2010). *Digestive diseases and sciences* 55(9): 2514-19.
- van Lierop, P.P., de Haar, C., Lindenberg-Kortleve, D.J., Simons-Oosterhuis, Y., van Rijt, L.S., Lambrecht, B.N., Escher, J.C., Samsom, J.N. and Nieuwenhuis, E.E. (2010). *Inflammatory bowel disease* 16(3): 442-51.
- Maruho Co.,Ltd. (2014) Drug interview form Protopic ointment 0.1% Revised 16th edition.
- Astellas Pharma Inc. (2014) Drug interview form Prograf capsules 0.5mg, 1mg, 5mg, granules 0.2mg, 1mg. Revised 34th edition
- Astellas Pharma Inc. (2014) Drug interview form Prograf capsules 0.5 mg, 1 mg, 5 mg, granules 0.2 mg, 1 mg. Revised 34th edition
- Novartis Pharma K.K. (2016). Drug interview form Simulect i.v. injection 20 mg. 10th edition.
- Sanofi K.K. (2018) Drug interview form Dupixent subcutaneous injection 300 mg syringe. 2nd edition.
- Taiho Pharmaceutical Co.,Ltd. (2013) Drug interview form IPD capsule 50 and 100. Revised 5th edition.
- Fujii Y., Gogi H., Takamura K., Sakuma A. and Goto T. *Kisotorinsyo* 31(8): 2693-2700 (in Japanese)
- Sengoku T., Morita K., Sato A., Sakuma S., Ogawa T., Hiroi J., Fujii T and Goto T. (1998) *Folia Pharmacol. Jpn.* (Nippon Yakurigaku Zasshi) 112, 221-232

## Appendix 1 - MIE, KEs and AO

### List of MIEs in this AOP

**Event: 980: Inhibition, Calcineurin Activity** (<https://aopwiki.org/events/980>)

Short Name: Inhibition, Calcineurin Activity

#### Key Event Component

| Process | Object                                 | Action    |
|---------|--|-----------|
| binding | FK506-binding protein 15               | increased |
| binding | FKBP12 ( <i>Arabidopsis thaliana</i> ) | increased |

#### AOPs Including This Key Event

| AOP ID and Name   | Event Type               |
|---|--------------------------|
| Aop:154 - Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response ( <a href="https://aopwiki.org/aops/154">https://aopwiki.org/aops/154</a> ) | MolecularInitiatingEvent |

#### Stressors

| Name                                  |
|---------------------------------------|
| Tacrorimus                            |
| Cyclosporin                           |
| Pimecrolimus                          |
| Dodecylbenzene sulfonate              |
| Dibefurin                             |
| Gossypol                              |
| Ascomycin                             |
| Kaempferol                            |
| 1,5-dibenzoyloxymethyl-norcantharidin |
| Tacrolimus (also FK506)               |

#### Biological Context

| Level of Biological Organization |
|----------------------------------|
| Molecular                        |



## *Evidence for Perturbation by Stressor*

### **Overview for Molecular Initiating Event**

CN inhibitory activities (IC50) are shown in follows.

Tacrolimus: 0.4nM

Cyclosporin: 7nM

Pimecrolimus: 0.4 nM

Dodecylbenzene sulfonate 9.3 uM

Dibefurin: 44 uM

Gossypol: 17 uM

Ascomycin: 0.7 nM

1,5-dibenzoyloxymethyl-norcantharidin: 7 uM

Kaempferol: 51.3 uM

## *Domain of Applicability*

### Taxonomic Applicability

| Term          | Scientific Term | Evidence | Links  |
|---------------|-----------------|----------|--|
| Homo sapiens  | Homo sapiens    | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> )   |
| Mus musculus  | Mus musculus    | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090</a> ) |
| Rattus rattus | Rattus rattus   | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10117">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10117</a> ) |

### Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

### Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

CN is broadly distributed in T-cells, B cells, and throughout the body. The structure of CnA and CnB is highly conserved from yeasts to humans. Also highly conserved are the amino acid sequences of the catalytic and regulatory domains of CnA isoforms from different organisms (Kincaid. 1996).

As for immunophilins, of which complexes inhibit the CN activity, FKBP is found in a wide variety of organisms, from prokaryotes to multicellular organisms (Siekierka et al. 1989a). Multiple subfamilies of FKBP have been reported, with at least eight types having been found in mammals. FKBP12 is reported to be expressed in B-cells, Langerhans cells and mast cells as well as in T-cells of humans, mice and other mammalian species.

Cyclophilins have been found in mammals, plants, insects, fungi and bacteria. They are structurally conserved throughout evolution and all living beings have PPIase activity (Wang P et al. 2005).

However, inhibition of CN phosphatase activity through immunophilin-CNI complex has been reported at least in rodents and humans.

### ***Key Event Description***

Calcineurin (CN) is a heterodimer that comprises a catalytic subunit (CnA), which handles phosphatase activity as well as calmodulin binding, and a Ca-binding regulatory subunit (CnB), which regulates intracellular calcium as well as CnA (Klee et al. 1988, Zhang et al. 1996). CnA, a 59kDa protein, has a serine-threonine phosphatase domain.

Immunophilins are a general class of proteins that exhibit peptidyl-propyl isomerase (PPIase) activity (Barik. 2006) and an immunophilin-CN inhibitor (CNI) complex such as FKBP12- FK506 and cyclophilin-CsA binds directly to CnA in the cell, causing steric hindrance of substrate binding to CN, which inhibits the phosphatase activity of CN without any contribution of PPIase activity (Schreiber and Crabtree 1992, Liu et al. 1993, Bierer et al. 1993, Bram et al. 1993, Rao et al. 1997, Liu et al. 1991).

### ***How it is Measured or Detected***

Phosphatase activity can be measured using a phosphatase assay. CN, calmodulin, FK506, and FKBP are incubated together, and the phosphatase activity is measured at various concentrations of FKBP. Kinetic analysis of FKBP12 concentration-dependent phosphatase activity and calculation of the CN inhibition constant  $K_i$  by the FKBP12-FK506 complex are conducted. (Bram et al. 1993). Phosphatase activity of CN in the presence of cyclosporin A (CsA), gossypol or dibefurin can also be determined in a similar manner (Sieber et al. 2009).

Immunophilin-CNI complexes directly inhibit phosphatase activity of CN, therefore, as a surrogate measurement of the CN activity, the binding of CsA with cyclophilin can be detected using an ELISA kit. Microtiter plates precoated with BSA and conjugated to cyclosporin are incubated with cyclophilin. Bound cyclophilin is then revealed by incubation with anti-cyclophilin rabbit antiserum followed by incubation with anti-rabbit globulin goat IgG coupled to alkaline phosphatase (Quesniaux et al. 1987).

### **References**

1. Barik, S. (2006). Immunophilins: for the love of proteins. Cellular and Molecular Life Sciences 63(24): 2889-900.
2. Bierer, B.E., Holländer, G., Fruman, D. and Burakoff, S.J. (1993). Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Current opinion in immunology 5 (5): 763-73.
3. Bram, R.J., Hung, D.T., Martin, P.K., Schreiber, S.L. and Crabtree, G.R. (1993). Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Molecular and cellular biology 13 (8): 4760-9.
4. Cameron, A.M., Nucifora, F.C. Jr., Fung, E.T., Livingston, D.J., Aldape, R.A., Ross, C.A. and Snyder, S.H. (1997). FKBP12 binds the inositol 1, 4, 5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. The Journal of biological chemistry 272 (44): 27582-8.
5. Hultsch, T., Albers, M. W., Schreiber, S.L. and Hohman, R. J. (1991). Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. Proceedings of the national academic science of the United States of America. 14:6229-6233.
6. Kang, C. B., Hong, Y., Dhe-Paganon, S. and Yoon, H. S. (2008). FKBP family proteins: immunophilins with versatile biological function. Neurosignals. 16: 318-325.

7. Kincaid, R.L. (1993). Calmodulin-dependent protein phosphatases from microorganisms to man. A study in structural conservatism and biological diversity. *Adv Second Messenger Phosphoprotein Res.* 1993;27:1-23.
8. Klee, C. B., Draetta, G. F. and Hubbard, M. J. (1988). Calcineurin. *Advances in enzymology and related areas of molecular biology.* 61:149-200.
9. Liu, J., Farmer, J. D. Jr., Lane, W. S., Friedman, J., Weissman, I., and Schreiber, S. L. (1991). Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell.* 66(4): 807-815.
10. Liu, J. (1993). FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. *Immunology today.* 14(6): 290-305.
11. Quesniaux VF, Schreier MH, Wenger RM, Hiestand PC, Harding MW, Van Regenmortel MH (1987). Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity.
12. Panhans-Gross, A., Novak, N., Kraft, S., and Bieber, T. (2001). Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). *Journal of Allergy and Clinical Immunology* 107(2): 345-52.
13. Rao, A., Luo, C., and Hogan, PG. (1997). Transcription factors of the NFAT family: regulation and function. *Annual Review of Immunology* 15: 707-47.
14. Schreiber, SL., and Crabtree, GR. (1992). The mechanism of action of cyclosporin A and FK506. *Immunology Today* 13(4): 136-42.
15. Sieber M., Baumgrass R., (2009). *Cell Commun Signal* Oct 27;7:2.
16. Siekierka, JJ., Hung, SH., Poe, M., Lin, CS., and Sigal, NH. (1989a). A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. *Nature* 341(6244): 755-57.
17. Siekierka, JJ., Wiederrecht, G., Greulich, H., Boulton, D., Hung, SH., Cryan, J., Hodges, PJ., and Sigal, NH. (1990). The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. *Journal of Biological Chemistry* 265(34): 21011-5.
18. Zhang, B.W., Zimmer, G., Chen, J., Ladd, D., Li, E., Alt, F.W., Wiederrecht, G., Cryan, J., O'Neill, E.A., Seidman, C.E., Abbas, A.K. and Seidman, J.G.. (1996). T cell responses in calcineurin A alpha-deficient mice. *Journal of experimental medicine* 183(2): 413-20.

## List of Key Events in the AOP

**Event: 979: Interference, nuclear localization of NFAT** (<https://aopwiki.org/events/979>)

Short Name: Interference, nuclear localization of NFAT

Key Event Component

| Process              | Object       | Action    |
|----------------------|--------------|-----------|
| genetic interference | NFAT protein | increased |

AOPs Including This Key Event

| AOP ID and Name   | Event Type |
|---|------------|
| Aop:154 - Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response ( <a href="https://aopwiki.org/aops/154">https://aopwiki.org/aops/154</a> ) | KeyEvent   |

Stressors

|                         |
|-------------------------|
|                         |
| Name                    |
| Tacrolimus (also FK506) |
| Cyclosporin             |

Biological Context

|                                  |
|----------------------------------|
|                                  |
| Level of Biological Organization |
| Molecular                        |

Organ term

|               |
|---------------|
| Organ term    |
| immune system |

## *Domain of Applicability*

### Taxonomic Applicability

| Term         | Scientific Term | Evidence | Links  |
|--------------|-----------------|----------|--|
| Homo sapiens | Homo sapiens    | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> )   |
| Mus musculus | Mus musculus    | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090</a> ) |

### Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

### Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

NFAT expresses in B cells, mast cells, neutrophils, granulocytes, dendritic cells, macrophages, and natural killer cells as well as T cells from humans, rodents and other mammalian species (Rao et al. 1997).

## *Key Event Description*

The nuclear factor of activated T cells (NFAT) is a substrate of calcineurin (CN) (Rao et al. 1997). A NFAT has an N-terminal with a plurality of SP motifs rich in serine and proline, which are controlled by means of phosphorylation and dephosphorylation. There is a nuclear localization signal (NLS) held between these SP regions as well as a nuclear export signal (NES) in the N-terminal adjacent to the SP motifs (Beals et al. 1997, Zhu and McKeon 1999, Serfling et al. 2000). SP motifs ordinarily are phosphorylated, which covers the NLS and leaves the NES exposed, so that NFAT localizes in cytoplasm. When SP motifs are dephosphorylated by activated CN, the NLS is exposed and the NES is covered, thereby promoting nuclear localization of NFAT (Matsuda and Koyasu 2000, Zhu and McKeon 1999). When T-cell activation takes place, T-cell-receptor- mediated stimulus increases the intracellular concentration of calcium and activates a regulatory subunit (CnB), which subsequently induces a catalytic subunit (CnA) phosphatase activation, leading to dephosphorylation of NFAT thereby promoting nuclear localization of NFAT. CNI-immunophilin complexes inhibit CN phosphatase activation, thereby interfering with NFAT nuclear localization (Bhattacharyya et al. 2011).

Concentration-dependent reduction of in vitro nuclear localization of NFAT was evident at concentrations from 0.1 nM (Jurkat T cells) or 10nM (human CD4<sup>+</sup> T cells) and up to 1  $\mu$ M (1000 nM) under the conditions of 2 hours treatment (Maguire et al. 2013).

## *How it is Measured or Detected*

Nuclear translocation of NFAT can be tested by imaging flowcytometer, in which lymphocytes are treated with fluorescence-labeled anti-NFAT antibody and DAPI (nuclear stain) and intracellular distribution of NFAT is analyzed by imaging flowcytometry with image analysis (Maguire O et al. 2013).

Interference with translocation of NFAT to the nucleus can be detected using gel mobility shift assays of nuclear or cytoplasmic extracts electrophoresed with end-labeled NFAT-binding site from human IL-2 enhancer (Flanagan et al. 1991).

## References

1. Rao, A., Luo, C., and Hogan, PG. (1997). Transcription factors of the NFAT family: regulation and function. *Annual Review of Immunology* 15: 707-47.
2. Beals, C.R., Clipstone, N.A., Ho, S.N. and Crabtree, G.R. (1997). Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin- sensitive intramolecular interaction. *Genes & development* 11 (7): 824-34.
3. Zhu, J. and McKeon, F. (1999). NF-AT activation requires suppression of Crm1-dependent export by calcineurin. *Nature*. 398(6724): 256-60.
4. Serfling, E., Berberich-Siebelt, F., Chuvpilo, S., Jankevics, E., Klein-Hessling, S., Twardzik, T., and Avots, A., (2000). The role of NF-AT transcription factors in T cell activation and differentiation. *Biochimica et Biophysica Acta* 1498 (1): 1-18.
5. Matsuda, S., Koyasu, S. (2000). A second target of cyclosporin A and FK506. *Tanpakushitsu kakusan koso*. 45(11): 1823-1831.
6. Bhattacharyya, S., Deb, J., Patra, A.K., Thuy Pham, D.A., Chen, W., Vaeth, M., Berberich-Siebelt, F., Klein-Hessling, S., Lamperti, E.D., Reifenberg, K., Jellusova, J., Schweizer, A., Nitschke, L., Leich, E., Rosenwald, A., Brunner, C., Engelmann, S., Bommhardt, U., Avots, A., Müller, M.R., Kondo, E. and Serfling, E. (2011). NFATc1 affects mouse splenic B cell function by controlling the calcineurin-NFAT signaling network. *The Journal of experimental medicine* 208 (4): 823-39.
7. Flanagan, W.M., Corthésy, B., Bram, R.J. and Crabtree, G.R. (1991). Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. *Nature* 352 (6338): 803-7.
8. Maguire O., Tornatore K.M., O'Loughlin K.L., Venuto R.C., Minderman H.(2013). Nuclear translocation of nuclear factor of activated T cells(NFAT) as a quantitative pharmacodynamic parameter for tacrolimus.

## Event: 981: Reduction, NFAT/AP-1 complex formation (<https://aopwiki.org/events/981>)

Short Name: Reduction, NFAT/AP-1 complex formation

Key Event Component

| Process   | Object                     | Action    |
|---|----------------------------|-----------|
| cytokine production involved in inflammatory response | NFAT activation molecule 1 | decreased |
| cell activation                                       |                            | increased |

AOPs Including This Key Event

| AOP ID and Name   | Event Type |
|---|------------|
| Aop:154 - Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response ( <a href="https://aopwiki.org/aops/154">https://aopwiki.org/aops/154</a> ) | KeyEvent   |

Stressors

| Name                    |
|-------------------------|
| Tacrolimus (also FK506) |
| Cyclosporin             |

Biological Context

| Level of Biological Organization |
|----------------------------------|
| Cellular                         |

Cell term

| Cell term |
|-----------|
| T cell    |

Organ term

| Organ term    |
|---------------|
| immune system |

## *Domain of Applicability*

### Taxonomic Applicability

| Term         | Scientific Term | Evidence | Links  |
|--------------|-----------------|----------|--|
| Homo sapiens | Homo sapiens    | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> )   |
| Mus musculus | Mus musculus    | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090</a> ) |

### Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

### Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

CN-NFAT system functionality is common among mammalian species, including humans and rodents. It is also possible that FK506-induced interference with NFAT/AP-1 complex formation at the promoter site of the IL-2 gene is common among mammalian T cells, including those of humans and rodents (Flanagan et al. 1991).

## *Key Event Description*

Activated nuclear factor of activated T cells (NFAT) that has localized to the nucleus binds cooperatively at the site of the Interleukin-2 (IL-2) promoter with activator protein-1 (AP-1), which is a heterodimer comprising a Fos and a Jun protein (Schreiber and Crabtree 1992, Jain et al. 1992), thereby inducing transcription of IL-2 (Jain et al. 1993). Interfered nuclear localization of NFAT, induced by FK506, hinders the formation of the functional NFAT/AP-1 complexes necessary to binding at the site of IL-2 promoters (Flanagan et al. 1991).

Besides IL-2, NFAT is known to bind cooperatively at the promoters of other T-cell cytokines, such as Interleukin-4 (IL-4) (Macian et al. 2005).

Treatment of activated T cells with FK506 at 100ng/mL (124nM) or CsA at 500ng/mL (416nM) for 2 hours hinders the formation of functional NFAT/AP-1 in the nucleus (Flanagan et al. 1991).

## *How it is Measured or Detected*

Reductions in NFAT/AP-1 complex formation can be detected using a gel shift assay to test nuclear extracts from either stimulated or unstimulated Ar-5 T cells with radio-labelled NFAT binding oligonucleotide from murine IL-2 promoter. Anti-Fos and anti-Jun antibodies are used to examine NFAT/AP-1 complex formation (Jain et al. 1992).

## References

1. Flanagan, W.M., Corthésy, B., Bram, R.J. and Crabtree, G.R. (1991). Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. *Nature* 352 (6338): 803-7.
2. Jain, J., McCaffrey, P. G., Valge-Archer, V. E. and Rao, A. (1992). Nuclear factor of activated T cells contains Fos and Jun. *Nature*. 356(6372): 801-804.



3. Jain, J., Miner, Z. and Rao, A. (1993). Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. Journal of immunology. 151(2): 837-848.
4. Macian, F. (2005). NFAT proteins: key regulators of T-cell development and function. Nature reviews. Immunology. 5(6): 472-84.
5. Schreiber, SL., and Crabtree, GR. (1992). The mechanism of action of cyclosporin A and FK506. Immunology Today 13(4): 136-42.

### Event: 1202: Suppression, IL-2 and IL-4 production (<https://aopwiki.org/events/1202>)

Short Name: Suppression, IL-2 and IL-4 production

Key Event Component

| Process                  | Object        | Action    |
|--------------------------|---------------|-----------|
| interleukin-2 production | interleukin-2 | decreased |
| interleukin-4 production | interleukin-4 | decreased |

AOPs Including This Key Event

| AOP ID and Name   | Event Type |
|---|------------|
| Aop:154 - Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response ( <a href="https://aopwiki.org/aops/154">https://aopwiki.org/aops/154</a> ) | KeyEvent   |

Stressors

| Name                     |
|--------------------------|
| Tacrolimus (also FK506)  |
| Cyclosporin              |
| Dexamethasone            |
| Azathioprine             |
| Methotrexate             |
| Benzo(a)pyrene           |
| Urethane                 |
| 1,2:5,6-dibenzanthracene |
| psychosocial stress      |

Biological Context

| Level of Biological Organization |
|----------------------------------|
| Cellular                         |

Organ term

|               |
|---------------|
| Organ term    |
| immune system |

### *Domain of Applicability*

#### Taxonomic Applicability

| Term                 | Scientific Term        | Evidence | Links  |
|----------------------|------------------------|----------|--|
| Homo sapiens         | Homo sapiens           | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> )   |
| Mus musculus         | Mus musculus           | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090</a> ) |
| cynomolgu<br>smonkey | Macaca<br>fascicularis | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9541">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9541</a> )   |

#### Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

#### Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

CNIs suppress production of IL-2, IL-3, IL-4, IL-5, IFN- $\gamma$ , Granulocyte Macrophage colony-stimulating Factor (GM-CSF), and other cytokines, as induced by CD2/CD3 or CD3/CD26 stimulation, in human peripheral blood mononuclear cells (PBMC) (Sakuma et al. 2001a). Also, CNIs (FK506 and CsA) suppress production of IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, Tumor Necrosis Factor- $\alpha$ , IFN- $\gamma$ , and GM-CSF, as induced by CD3/PMA stimulation, in human PBMC (Dumont et al. 1998).

CNIs (FK506 and CsA) exhibit suppression of IL-2 production induced from mixed lymphocyte reactions in mice and humans (Kino, T et al. 1987a).

Treatment with CsA or 2C1.1 resulted in reduction of IL-2, IL-4, IL-5, and IL-17 cytokine production from PMA/ionomycin stimulation of whole blood in the cynomolgus monkey (Kevin, G. et al. 2014).

These facts indicate that Calcineurin-NFAT system-mediated suppression of cytokines is commonly found in humans, monkey and mice.

### *Key Event Description*

Production of T cell cytokines including Interleukin (IL)-2 and IL-4 is regulated by nuclear factor of activated T cells (NFAT)/ activator protein-1 (AP-1) complexes. Activated NFAT/AP-1 complex that bind at the site of the IL-2 and IL-4 promoters, thereby induces transcription of IL-2 and IL-4 (Jain et al. 1993). For IL-2, NFAT proteins are necessary for IL-2 gene expression and cooperation of NFAT with AP-1 is required for IL-2 gene transcription. For IL-4, At least five different NFAT sites have been described in the IL-4 promoter with at least three of them being composite sites binding NFAT and AP-1 (Macián et al. 2001).

IL-2 binds to IL-2 receptor (IL-2R) and acts on T cells. CD25 is one of IL-2R. Basiliximab (Simulect) is known as anti-CD25 antibody. Basiliximab binds to IL-2R and blocks IL-2 signaling. Clinical transplantation study of basiliximab

reveals decreases in rejections. On the other hand, basiliximab inhibits the activation of antigen specific T cells (Novartis Pharma 2016).

Calcineurin inhibitors (CNIs) such as FK506 and cyclosporin A (CsA) hinder the formation of the functional NFAT/AP-1 complexes by interfering with NFAT nuclear localization (Flanagan et al. 1991). Reduced binding of NFAT/AP-1 complexes at the promoter site of the IL-2 gene lowers the transcription of the mRNA of IL-2 and the following cytokine production.

Transcription of IL-4 is also inhibited by CNIs in the same manner as IL-2 (Dumont et al. 1998).

In CD3/ phorbol 12-myristate-13-acetate (PMA)-activated human T cells, FK506 suppressed production of IL-2, IL-4, and Interferon (IFN)- $\gamma$  at the concentrations of 1.2 to 12.5 nM after 22 to 24 hours culture as well as inhibited expression of IL-2, IL-4, and IFN- $\gamma$  mRNA at 10 nM (Dumont et al. 1998).

Treatment with CsA completely eliminated detectable IL-2 release from 3A9 T cells co-cultured with antigen-bearing Ch27 B cells with an IC<sub>25</sub> and IC<sub>50</sub> for IL-2 production of 1.19 nM and 1.99 nM. Treatment with other immunosuppressant compounds (dexamethasone, azathioprine, methotrexate, benzo(a)pyrene and urethane) also resulted in decreased IL-2 release from stimulated 3A9 T cells at non-cytotoxic concentrations. Urethane, a weakly immunosuppressive chemical, was least potent in the assay, with an IC<sub>25</sub> and IC<sub>50</sub> for IL-2 secretion of 4.24 mM and 13.26 mM (D.M. Lehmann. et al. 2018).

In male CD-1 mice, chronic psychosocial stress (types of social outcome occurred: residents becoming subordinates) reduced IL-2 release in response to keyhole limpet hemocyanine (KLH) (Alessandro, B. et al. 2003).

In female B6C3F1 mice, 1,2:5,6-dibenzanthracene exposure reduced production of IL-2 in spleen cell culture supernatants after in vitro stimulation with Concanavalin A or lipopolysaccharide (Donna, C. et al. 2010).

Treatment with CsA at 50 mg/kg BID via oral gavage or 2C1.1 (a fully human anti-ORAI1 monoclonal antibody) at 25 mg/kg single IV resulted in reduction of IL-2, IL-4, IL-5, and IL-17 cytokine production from PMA/ionomycin stimulation of whole blood in the cynomolgus monkey (Kevin, G. et al. 2014).

CNIs is considered to increase carcinogenicity through the suppression of IL-2 and IL-4 production.

- Renal transplant patients on immunosuppressive therapy were found to develop cancer within 10 years after surgery (Luster, M.I. et al. 1993).

In experimental animal studies, carcinogenicity of FK506 was reported as follows.

- In mice subjected to topical application testing, in which 100  $\mu$ L of FK506 ointment was applied once daily for two years to roughly 40% of the total body area, an increased incidence of lymphoma was found in mice of the 0.1% ointment group showing high blood concentrations of the drug (Maruho Co., Ltd 2014).
- In hairless albino mice, virtually all of which developed skin tumors after a 40-week exposure to ultraviolet light, application of a 1% FK506 ointment reduced the time to outbreak of the skin tumors. (Maruho Co., Ltd 2014).

### *How it is Measured or Detected*

Quantitation of cytokine content was done on appropriately diluted samples, run in duplicate, using Sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA) kits to test matched Antibody pairs with biotin-horseradish peroxidase-streptavidin detection and 3,3',5,5'-tetramethylbenzidine substrate. ELISA plates were scanned in a Molecular Devices UVmax plate reader (Menlo Park, CA), using SOFT max software (Molecular Devices) (Dumont et al. 1998).

Ex vivo whole blood stimulated cytokine (IL-2, IL-4, IL-5, and IL-17) production assay in the supernatants were determined using an electrochemiluminescent immunoassay from Meso Scale Discovery (MSD; Gaithersburg, MD) (Kevin, G. et al. 2014).

Total RNA was extracted using RNeasy mini kit (Qiagen, Chatsworth, CA) and quantitated by absorbance at 260 nm. Cytokine mRNAs were detected using a RiboQuant MultiProbe RPA system (PharMingen, San Diego, CA). Riboprobes were 32P-labeled and hybridized overnight with 10 to 30 mg of the RNA samples. The hybridized RNA was treated with RNase and purified according to the RiboQuant protocol. The samples were then electrophoresed in 6% polyacrylamide-Tris-borate-EDTA-urea gels using the Seqi -Gen GT Nucleic Acid Electrophoresis Cell (Bio-Rad, Hercules, CA), or minigels (Novex, San Diego, CA). The gels were dried, exposed and quantitated in a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) using the ImageQuant software (Dumont et al. 1998).

## References

1. Dumont, F.J., Staruch, M.J., Fischer, P., DaSilva, C. and Camacho, R. (1998). Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. *Journal of immunology* 160 (6): 2579-89.
2. Flanagan, W.M., Corthésy, B., Bram, R.J. and Crabtree, G.R. (1991). Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. *Nature* 352 (6338): 803-7.
3. Jain, J., McCaffrey, P. G., Valge-Archer, V. E. and Rao, A. (1992). Nuclear factor of activated T cells contains Fos and Jun. *Nature*. 356(6372): 801-804.
4. Jain, J., Miner, Z. and Rao, A. (1993). Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. *Journal of immunology*. 151(2): 837-848.
5. Kino, T., Hatanaka, H., Miyata, S., Inamura, N., Nishiyama, M., Yajima, T., Goto, T., Okuhara, M., Kohsaka, M. and Aoki, H. (1987a). FK-506, a novel immunosuppressant isolated from a *Streptomyces*. II. Immunosuppressive effect of FK-506 in vitro. *Journal of antibiotics*. 40(9): 1256-1265.
6. Macián, F., López-Rodríguez, C. and Rao, A. (2001). Partners in transcription: NFAT and AP-1. *Oncogene*. 20(19): 2476-89.
7. Novartis Pharma K.K. (2016). Drug interview form Simulect i.v. injection 20 mg. 10th edition.
8. Sakuma, S., Higashi, Y., Sato, N., Sasakawa, T., Sengoku, T., Ohkubo, Y., Amaya, T., and Goto, T. (2001a). Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). *International Immunopharmacology* 1(6): 1219-26.
9. Schreiber, S.L., and Crabtree, G.R. (1992). The mechanism of action of cyclosporin A and FK506. *Immunology Today* 13(4): 136-42.
10. Luster, M.I., and Rosenthal, G.J. (1993). *Environmental Health Perspectives*. 100: 219-36.
11. Maruho Co., Ltd. (2014) Drug interview form Protopic ointment 0.1% Revised 16th edition.
12. Alessandro B, Paola S, Alberto E. Paneraic, Tiziana P, Paola Palanza and Stefano P (2003). Chronic psychosocial stress-induced down-regulation of immunity depends upon individual factors *Journal of Neuroimmunology* 141: 58-64
13. Donna C. S, Matthew J. S and Kimber L. W Jr. (2010) Systemic immunosuppression following a single pharyngeal aspiration of 1,2:5,6-dibenzanthracene in female B6C3F1 mice, *Journal of Immunotoxicology*, 7:3, 219-231
14. Kevin G, Hossein S, Raju S, Valerie A, Anna K, Ming Z, Fen-Fen L, Hung Q. N, Lei Z, John K. S, Min W and Helen J. M (2015) Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkey, *Journal of Immunotoxicology*, 12:2, 164-173,
15. D.M. Lehmann, W.C. Williams. (2018) Development and Utilization of a Unique In Vitro Antigen Presentation Co-culture Model for Detection of Immunomodulating Substances. *Toxicol In Vitro*. 53: 20-28.

## List of Adverse Outcomes in this AOP

**Event: 984: Impairment, T-cell dependent antibody response** (<https://aopwiki.org/events/984>)

Short Name: Impairment, T-cell dependent antibody response

Key Event Component

| Process           | Object | Action    |
|-------------------|--------|-----------|
| Immunosuppression |        | increased |

AOPs Including This Key Event

| AOP ID and Name   | Event Type      |
|---|-----------------|
| Aop:154 - Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response ( <a href="https://aopwiki.org/aops/154">https://aopwiki.org/aops/154</a> ) | Adverse Outcome |

Stressors

| Name                     |
|--------------------------|
| Tacrolimus (also FK506)  |
| Cyclosporin              |
| 1,2:5,6-dibenzanthracene |
| psychosocial stress      |

Biological Context

| Level of Biological Organization |
|----------------------------------|
| Individual                       |

### *Domain of Applicability*

Taxonomic Applicability

| Term              | Scientific Term     | Evidence | Links  |
|-------------------|---------------------|----------|--|
| Homo sapiens      | Homo sapiens        | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> )   |
| Mus musculus      | Mus musculus        | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090</a> ) |
| Rattus norvegicus | Rattus norvegicus   | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10116">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10116</a> ) |
| cynomolgus monkey | Macaca fascicularis | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9541">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9541</a> )   |

Life Stage Applicability

| Life Stage | Evidence |
|------------|----------|
|            |          |

|                 |      |
|-----------------|------|
| All life stages | High |
|-----------------|------|

#### Sex Applicability

|            |          |
|------------|----------|
| Sex        | Evidence |
| Unspecific | High     |

CNIs induced impairment of TDAR is demonstrated with rodent studies. That is, oral administration of FK506 or CsA to mice for 4 days impaired the response of PFC in splenocytes after intravenous immunization with sheep erythrocytes (Kino et al. 1987). Likewise, oral administration of FK506 to rats over a four-week period reduced production of both anti-KLH-IgG and IgM antibodies after subcutaneous immunization with KLH (Ulrich et al. 2004). Moreover, Treatment with CsA at 50 mg/kg BID via oral gavage in cynomolgus monkey resulted in reduction of serum SRBC-specific IgM and IgG (Kevin, G. et al. 2014). As for humans, in vitro experiments showed that treatment with FK506 or CsA of peripheral blood mononuclear cells from blood-bank donors suppressed the production of IgM and IgG antibodies specific to T-cell-dependent antigens. (Heidt et al, 2009) Also, in SKW6.4 cells (IL-6-dependent, IgM-secreting, human B-cell line) cultures, FK506 or CsA suppressed the production of IgM antibodies in the presence of T-cell activation. (Sakuma et al. 2001b) Considering that FK506 and CsA reduce T cell-derived cytokines including IL-2 and IL-4, these findings strongly suggest that impairment of TDAR following reduced production of such cytokines occurs at least in common among humans monkey and rodents.

#### *Key Event Description*

Antibody production to T-cell-dependent antigens is established through the coordination of B cells, antigen-presenting cells as well as T-cell-derived cytokines, which stimulate B cells to proliferate and differentiate. T-cell-dependent antibody response (TDAR) might be altered if any of these cell populations is affected.

Interleukin (IL)-2 stimulates B cells to proliferate through surface IL-2 receptors. IL-4 stimulates B-cells to proliferate, to switch immunoglobulin classes, and to differentiate into plasma and memory cells. Suppressing the production of these B-cell-related cytokines appears to impair TDAR, as seen in the result of FK506 treatment (Heidt et al, 2009).

IL-2 and IL-4 are produced and secreted by helper T cells and play important roles in the development of TDAR. IL-4 affects maturation and class switching of B cells as well as proliferation, both of which induces/enhances T cell dependent antibody production. IL-2 promotes differentiation of B cells through IL-2 stimulates differentiation of the activated T cell into T cell called Th2 cell. Therefore, suppressed production of IL-2 and IL-4 impairs TDAR (Alberts et al. 2008).

In male CD-1 mice, chronic psychosocial stress (types of social outcome occurred: residents becoming subordinates) decrease in anti-keyhole limpet hemocyanine (KLH) immunoglobulin (Ig)G. (Alessandro, B. et al. 2003).

In female B6C3F1 mice, 1,2:5,6-dibenzanthracene (DBA) exposure reduced total IgG antibody in spleen cell culture supernatants after in vitro stimulation with lipopolysaccharide (LPS) (Donna, C. et al. 2010).

Treatment with cyclosporin A (CsA) at 50 mg/kg BID via oral gavage in cynomolgus monkey resulted in reduction of serum sheep red blood cells (SRBC)-specific IgM and IgG (Kevin, G. et al. 2014).

After a 9-day culture of B cells and non-pre-activated T cell stimulation with FK506 or CsA, the levels of IgM and IgG in the culture supernatant were reduced at 0.3 and 1.0 ng/mL (0.37 and 1.24 nM) of FK506 or 50 and 100 ng/mL (41.6 and 83.2 nM) of CsA (Heidt et al, 2009).

After a 4-day culture of SKW6.4 cells (IL-6-dependent IgM-secreting human B-cell line) and anti-CD3/CD28 stimulated peripheral blood mononuclear cells (PBMC) culture supernatant with FK506 or CsA, the level of IgM in the culture supernatant was reduced at concentrations of 0.01 to 100 ng/mL (0.012 to 124 nM) of FK506 or 0.1 to 1000 ng/mL (0.083 to 83.2 nM) of CsA (Sakuma et al. 2001b).

Rats were treated with FK506 for over four weeks and immunized with KLH, after which serum concentration of anti-KLH IgM and IgG was reduced at the dose level of 3 mg/kg/day (Ulrich et al. 2004).

Mice were treated with FK506 or CsA for 4 days, and immunized with SRBC, after which antigen-specific plaque-forming splenocytes were reduced at dose levels of 3.2, 10, 32 and 100 mg/kg of FK506 or 32 and 100 mg/kg of CsA (Kino et al. 1987b).

As immunosuppression-derived adverse outcomes by calcineurin inhibition, FK506 and CsA increase the frequency and/or severity of infections and allergic reactions impaired TDAR seems to be one of the causative factors for these side effects. Some clinical trials of FK506 and CsA revealed these adverse effects as follows.

- In clinical trials of renal transplantation using FK506 or CsA, opportunistic infections such as candida, cytomegalovirus and herpes simplex virus were reported (Ekberg et al. 2007).
- In recipients of liver transplants treated with FK506 or CsA, opportunistic infections such as cytomegalovirus, hepatitis C virus, hepatitis B and herpes simplex virus were reported (Fung et al. 1991).
- Cardiac transplant patients treated with cyclosporin developed pulmonary infections within the first year after surgery (Luster, M.I. et al. 1993).
- In patients of X-linked autoimmune enteropathy treated with CsA or FK506, serum levels of IgE developed extremely high during the immunosuppressive therapy (Kawamura et al. 1997).
- Renal transplant recipients treated with belatacept/mycophenolate (MMF)/prednisone or FK506/MMF/prednisone showed significantly lower the geometric mean hemagglutination inhibition titer against influenza vaccine, hemagglutination-specific IgG and isotype IgG1 antibodies, and IgG-antibody secreting cells response (Gangappa et al. 2019).

### *How it is Measured or Detected*

TDAR could be examined in vivo and in vitro.

In vivo studies of antigen-specific antibodies are usually performed by measuring serum antibody levels with Enzyme-Linked Immunosorbent Assay (ELISA) or with a plaque-forming cell (PFC) assay.

- Rats were repeatedly administered FK506 orally for 4 weeks and immunized with KLH, after which the serum was examined for T-cell-dependent, antigen-specific, IgM and IgG levels using a Sandwich ELISA kit (Ulrich et al. 2004).
- Mice were repeatedly administered calcineurin inhibitors (CNIs) including FK506 and CsA orally for 4 days and immunized with SRBC, after which spleen cells were examined using a PFC assay (Kino et al. 1987).
- Cynomolgus monkeys received 50 mg/kg CsA twice a day via oral gavage (10 h apart) for 23 days and were immunized with SRBC, after which the serum was examined for Anti-SRBC IgM and IgG levels using an ELISA specific for SRBC antigen (Kevin, G. et al. 2014).
- Mice were exposed a single pharyngeal aspiration of DBA, after which supernatants of splenocytes cultured for 24 h in the presence of LPS and assayed using a mouse IgM or IgG matched pairs antibody kit (Bethyl Laboratories, Montgomery, TX) (Donna, C. et al. 2010).

For in vitro studies, total IgM and IgG levels in culture supernatant are often measured after polyclonal T-cell activation rather than measuring antigen stimulation in immune cell cultures.

- T cells and B cells isolated from human peripheral blood mononuclear cells (PBMC) were co-cultured with a CNIs for nine days in the presence of polyclonal-T-cell stimulation, after which supernatants were tested for immunoglobulin IgM and IgG levels using a Sandwich ELISA kit. Treatment with FK506 or CsA reduced the levels of IgM and IgG at the concentrations of 0.3 and 1.0 ng/mL or 50 and 100 ng/mL (Heidt et al, 2009). SKW6.4 cells (IL-6-dependent IgM-secreting human B-cell line) were cultured with anti-CD3/CD28 antibody-stimulated PBMC culture supernatant. After culturing for four days, IgM produced in the culture

- supernatants was measured using an ELISA kit. FK506 or CsA reduced the levels of IgM at the concentrations of 0.01 to 100 ng/mL or 0.1 to 1000 ng/mL (Sakuma et al. 2001b).
- In order to examine class switching, T cells derived from human PBMCs were cultured with CNIs, and cytokine mRNA levels of Interferon-gamma, IL-2, IL-4, IL-5, IL-10, IL-13, and other B-cell-stimulatory cytokines produced in T cells were measured by quantitative PCR (Dumont et al. 1998).

### *Regulatory Significance of the AO*

The ICH S8 guideline, which covers immunosuppression of small molecule drugs, determines the need for immunotoxicity studies by comprehensively evaluating the findings of pharmacology, changes in the immune system in repeated-dose toxicity studies, and other factors using a Weight of Evidence approach. If there is concern about immunotoxicity, the presence or absence of immunotoxicity should be determined using an in vivo test system capable of assessing the functional changes of predicted immunotoxic target cells. If immunotoxicity is observed, additional studies including in vitro assays or clinical evaluation should be considered to assess the risk of immunotoxicity in humans. Because TDAR involves many immune cell populations, including T cells, B cells, and antigen-presenting cells, evaluation of TDAR is recommended when there is concern about immunotoxicity but the immunotoxic target cells are unclear. The S8 guidelines list KLH, SRBC, and tetanus toxin as antigens for TDAR.

The draft FDA immunotoxicity testing guidance (2020) covers immunosuppressive and immunostimulatory drugs and biologics; evaluating immunosuppressive drugs in the draft FDA guidance is similar to that in the S8 guideline, with in vivo TDAR assays recommended when toxic target cells are unknown. The draft guidance states that TDAR assays using KLH as an antigen have been established in mice, rats, dogs, minipigs, and cynomolgus monkeys, but the use of SRBC and tetanus toxin as antigens is also acceptable.

For the assessment for pesticides, US EPA OPPTS 870.7800 immunotoxicity testing guideline recommends TDAR using SRBC. The REACH guideline does not provide for immunotoxicity testing, but it provides triggers for conducting immunotoxicity testing.

The WHO/IPSS Immunotoxicity Risk assessment Guidance (2012) describes a strategy for assessing five categories of immunotoxicity risks, including immunosuppression. For risk assessment of immunosuppression, it calls for identification of immunosuppression risks, prediction of pathogenesis that may occur, and consideration of safety margins based on the WoE approach from human findings, infection resistance tests, immune function tests, general immune system assays, histopathological findings and organ weights in general toxicity studies, and hematological data.

The evaluation of immunotoxicity in F1 animals in the OECD Guidelines for Extended First Generation Reproductive and Developmental Toxicity Studies (TG443) requires that PFC and ELSA assays to measure primary IgM antibody production by TDAR using T-cell dependent antigens (SRBC, KLH, etc.) be performed. Furthermore, if changes are observed, the significance of the changes should be examined by comprehensively evaluating other data.

The outcomes of immunosuppression are susceptibility to infection and tumorigenesis, and the FDA guidance requires that immunosuppressive drugs be evaluated for carcinogenic risk using WoE approach based on the results of carcinogenicity and immunotoxicity studies. Meanwhile, the ICH S1B(R1) Draft Step 2 Guidelines for Carcinogenicity Testing calls for evaluation of carcinogenicity by WoE approach instead of rat carcinogenicity testing, because rodent carcinogenicity test models are less capable of detecting carcinogenicity. On the other hand, it is difficult to define susceptibility to infection as a measurable AO with a clear mechanism, because immune responses vary among pathogens. In fact, many immunotoxicity guidelines require that the risk of immunotoxicity be identified and assessed by evaluating immune functions.

In AOP154, it was difficult to define susceptibility to infection as an AO for the AOP154, so TDAR, which is recommended as an indicator of immunosuppression in many guidelines, was used as an AO. It is expected that several AOPs with TDARs as AOs will be developed, and based on these AOPs, it may be possible to develop an IATA to assess the risk of immunotoxicity characterized by TDARs.



## References

1. Alberts, B., Johnson, A., Lewis, L., Raff, M., Roberts, K. and Walter, P. (2008). *Molecular Biology of the Cell*. 5th ed., Garland Science, New York. 1539-1601
2. Heidt, S., Roelen, D. L., Eijssink, C., Eikmans, M., van Kooten, C., Claas, F. H. and Mulder, A. (2010). Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. *Clinical and experimental immunology*. 159(2): 199-207.
3. Sakuma, S., Kato, Y., Nishigaki, F., Magari, K., Miyata, S., Ohkubo, Y., and Goto, T. (2001b). Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. *International Immunopharmacology* 1(4): 749-57.
4. Kino, T., Hatanaka, H., Hashimoto, M., Nishiyama, M., Goto, T., Okuhara, M., Kohsaka, M., Aoki, H. and Imanaka, H. (1987). FK-506, a novel immunosuppressant isolated from a *Streptomyces*. I. Fermentation, isolation, and physico-chemical and biological characteristics. *Journal of antibiotics*. 40(9): 1249-1255.
5. Ulrich, P., Paul, G., Perentes, E., Mahl, A., and Roman D. (2004). Validation of immune function testing during a 4-week oral toxicity study with FK506. *Toxicology Letters* 149(1-3): 123-31.
6. Dumont, F.J., Staruch, M.J., Fischer, P., DaSilva, C. and Camacho, R. (1998). Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. *Journal of immunology* 160 (6): 2579-89.
7. Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, S., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J.M., Frei, U., Vanrenterghem, Y., Daloze, P. and Halloran, P.F.; ELITE-Symphony Study. (2007). Reduced exposure to calcineurin inhibitors in renal transplantation. *The New England journal of medicine* 357 (25): 2562-75.
8. Fung, J., Abu-Elmagd, K., Jain, A., Gordon, R., Tzakis, A., Todo, S., Takaya, S., Alessiani, M., Demetris, A., Bronster, O., Martin, M., Miele, L., Selby, R., Reyes, J., Doyle, H., Stieber, A., Casavilla, A. and Starzl, T. (1991). A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. *Transplantation proceedings* 23 (6): 2977-83.
9. Luster, M.I., and Rosenthal, G.J. (1993). *Environmental Health Perspectives*. 100: 219-36.
10. Alessandro B, Paola S, Alberto E. Paneraic, Tiziana P, Paola Palanza and Stefano P (2003). Chronic psychosocial stress-induced down-regulation of immunity depends upon individual factors *Journal of Neuroimmunology* 141: 58-64
11. Donna C. S, Matthew J. S and Kimber L. W Jr. (2010) Systemic immunosuppression following a single pharyngeal aspiration of 1,2:5,6-dibenzanthracene in female B6C3F1 mice, *Journal of Immunotoxicology*, 7:3, 219-231
12. Kevin G, Hossein S, Raju S, Valerie A, Anna K, Ming Z, Fen-Fen L, Hung Q. N, Lei Z, John K. S, Min W and Helen J. M (2015) Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkey, *Journal of Immunotoxicology*, 12:2, 164-173,
13. Gangappa S, Wrammert J, Wang D, Li ZN, Liepkalns JS, Cao W, Chen J, Levine MZ, Stevens J, Sambhara S, Begley B, Mehta A, Pearson TC, Ahmed R, Larsen CP. (2019) Kinetics of antibody response to influenza vaccination in renal transplant recipients. *Transpl Immunol*. 53:51-60.
14. Kawamura N, Furuta H, Tame A, Kobayashi I, Ariga T, Okano M, Sakiyama Y. (1997) Extremely high serum level of IgE during immunosuppressive therapy: paradoxical effect of cyclosporine A and tacrolimus. *Int Arch Allergy Immunol*. 112(4):422-4.

## Appendix 2: List of Key Event Relationships in the AOP

### List of Adjacent Key Event Relationships

**Relationship: 1508: Inhibition, Calcineurin Activity leads to Interference, nuclear localization of NFAT**  
(<https://aopwiki.org/relationships/1508>)

AOPs Referencing Relationship

| AOP Name   | Adjacency | Weight of Evidence | Quantitative Understanding |
|--|-----------|--------------------|----------------------------|
| Inhibition of Calcineurin Activity Leading to Impaired T-Cell DependentAntibody Response ( <a href="https://aopwiki.org/aops/154">https://aopwiki.org/aops/154</a> ) | adjacent  | Moderate           | Moderate                   |

### *Evidence Supporting Applicability of this Relationship*

#### Taxonomic Applicability

| Term            | Scientific Term | Evidence | Links  |
|-----------------|-----------------|----------|--|
| Homo sapiens    | Homo sapiens    | Moderate | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> )   |
| Mus musculoides | Mus musculoides | Moderate | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=60742">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=60742</a> ) |

#### Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

#### Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

CN is broadly distributed throughout the body, and the structure of CnA and CnB is highly conserved from yeasts to humans (Kincaid. 1993).

NFAT expresses in B cells, mast cells, neutrophils, granulocytes, dendritic cells, macrophages, and natural killer cells as well as T cells from humans, rodents and other mammalian species (Rao et al. 1997).

FKBP is found in a wide variety of organisms, from prokaryotes to multicellular organisms (Siekierka et al. 1989). Multiple subfamilies of FKBP have been reported, with at least eight types having been found in mammals. FKBP12 is reported to be expressed in B-cells, Langerhans cells, and mast cells as well as in T-cells of humans, mice and other mammalian species.

Cyclophilins have been found in mammals, plants, insects, fungi and bacteria. They are structurally conserved throughout evolution and all have PPIase activity (Wang P et al. 2005). They form binary complexes with their ligand cyclosporine A.

These facts indicate that CN and immunophilins are conserved among animals and plants although they show multiple physiological functions.

In addition, CNI/immunophilin complex-induced inhibition of CN phosphatase activity resulting in suppression of immune responses is found in humans and mice.

### *Key Event Relationship Description*

The phosphatase activity of calcineurin (CN) is known to be inhibited by CN inhibitors (CNIs) such as FK506 and cyclosporin A (CsA) through the formation of complexes with immunophilins.

Immunophilins of FK506-binding protein (FKBP) and cyclophilin bind with CNIs FK506 and CsA to form complexes, which inhibit CN activity (Barik. 2006).

While FKBP12, FKBP12.6, FKBP13, and FKBP52 are all part of the FK506-binding FKBP family, FKBP12 has a significant involvement in the mechanism of action for FK506-induced immunosuppression (Siekierka et al. 1989, Kang et al. 2008).

FKBP12 is a 12-kDa protein localized in cytoplasm and has been isolated from Jurkat T-cells as a receptor that binds to FK506 (Bram et al. 1993). FKBP12 has an FK506-binding domain (FKBD) that comprises 108 amino acids, and is expressed in T cells, B cells, Langerhans cells, and mast cells (Siekierka et al. 1990, Panhans-Gross et al. 2001, Hultsch et al. 1991).

Cyclophilin and FKBP both exhibit peptidyl propyl isomerase (PPIase) activity, but inhibition of PPIase activity is not related to CN regulation.

CN is a heterodimer that comprises a catalytic subunit (CnA) and a Ca-binding regulatory subunit (CnB). CnA handles phosphatase activity as well as calmodulin binding, and CnB regulates intracellular calcium and CnA (Klee et al. 1988, Zhang et al. 1996). CnA is a 59kDa protein with a serine-threonine phosphatase domain.

CNI-immunophilin complexes such as FK506/FKBP complexes and cyclophilin/CsA complexes bind directly to CnA in the cell, causing steric hindrance of substrate binding to CN, which in turn inhibits phosphatase activity of CN (Schreiber and Crabtree 1992, Liu et al. 1993, Bierer et al. 1993, Bram et al. 1993, Rao et al. 1997, Liu et al. 1991).

The nuclear factor of activated T cells (NFAT) is a substrate of CN (Rao et al. 1997).

When T-cell activation takes place, T-cell–receptor-mediated stimulus increases the intracellular concentration of calcium and activates CnB, which subsequently induces CnA phosphatase activation, leading to dephosphorylation of NFAT. In that process, dephosphorylated SP motifs expose the nuclear localization signal (NLS) and cover nuclear export signal (NES), thereby promoting nuclear localization of NFAT (Matsuda and Koyasu 2000, Zhu and McKeon 1999).

When CN activity is inhibited by the binding of immunophilin complexes, dephosphorylation does not occur in NFAT, thereby resulting in nuclear export.

### ***Evidence Supporting this KER***

#### **Biological Plausibility**

The molecular structures and functions of CN and NFAT are based on sufficient scientific evidence as mentioned above. The known mechanisms for inhibition of CN phosphatase activity by FK506, CsA, or other CNIs are initiated by the formation of complexes with their respective immunophilin species. Immunophilins are general classes of proteins that exhibit PPIase activity, but the isomerase activity per se is not relevant for CN activity indicating that the latter is affected by the molecular structure of the complex (Schreiber and Crabtree 1992, Liu et al. 1993, Bierer et al. 1993, Bram et al. 1993, Rao et al. 1997, Liu et al. 1991).

As mentioned above, inhibition of CN phosphatase activity interferes with the dephosphorylation of NFAT, which leads to the suppression of its nuclear localization.

#### **Empirical Evidence**

Much experimental data is available that supports the inhibition of CN activity induced by CNI/immunophilin complexes, which subsequently suppress nuclear localization of NFAT. In addition, CN phosphatase activity is inhibited by 24 hours treatment with CNI of FK506 and CsA with IC<sub>50</sub> values of 0.5 and 5 nM, respectively (Fruman et al. 1992).

Also, concentration-dependent reduction of in vitro nuclear localization of NFAT was evident using imaging flowcytometry at the maximum concentration of 1 μM with minimal concentration of 0.1nM (Jurkat human T cell line) or 10nM (T cells from whole blood) after 2 hours treatment of tacrolimus (Maguire et al. 2013). Interference with translocation of NFAT to the nucleus is also detected using gel mobility shift assay to test nuclear extracts and cytoplasmic extracts, in which the examined concentration of FK506 was 10ng/mL (Flanagan et al. 1991).

These findings show that dose responses and temporality of MIE and KE1 seem to be the same.

## Uncertainties and Inconsistencies

CN and NFAT are expressed in T cells and other immune cells including B cells, DC, and NKT cells and related to cytokine productions from these immune cells. Also, expression of IL-2 receptors (IL-2R) in DCs are lowered due to the inhibition of CN phosphatase activity by CNI treatment. Of these, reduced production of IL-2 and IL-4 from T cells plays a major role in suppression of TDAR due to lower proliferation, differentiation, and class switching of B cells. There have been no reports of CNI-induced reduction of cytokines other than IL-2 and IL-4 or reduced expression of IL-2R resulting in TDAR suppression.

FKBP12, a specific immunophilin that binds with FK506, is also an accessory molecule that binds to IP3 and Ryanodine receptors, both of which occur in Ca channels located on the membrane of the endoplasmic reticulum and participate in the regulation of intracellular Ca concentration. When binding with FK506, FKBP12 leaves these receptors to increase the influx of  $\text{Ca}^{2+}$  from the endoplasmic reticulum to cytoplasm, which should increase CN activity. Treatment with FK506, however, suppresses NFAT nuclear localization. In addition, FKBP12-knock out mice show no changes in immune function, including T-cell function. These facts suggest that the inhibition of CN-NFAT systems induced by FK506 treatment results from direct inhibition of CN phosphatase activity by FK506/FKBP12 complexes and not by affecting Ryanodine and IP3 receptors associated with FKBP12.

### *Quantitative Understanding of the Linkage*

#### **Response-response relationship**

##### **MIE:**

Dose-response analysis of the effects of FK506 on CN phosphatase activity in mast cell-derived KiSVMC4W cells transfected with human FKBP12 cDNA showed that increased expression of FKBP12 resulted in a greater than ten-fold increase in sensitivity to FK506-mediated inhibition, as indicated by an  $\text{IC}_{50}$  value of roughly 2 nM with linear inverse dose-response curve after 1 hour incubation (Fruman et al.1995). Another phosphatase assay showed that FK506 inhibition of CN activity was concentration-dependent reverse sigmoidal and that  $\text{IC}_{50}$  values for CN inhibition were approximately 0.5 nM for FK 506 and 5 nM for CsA after 1 hour culture (Fruman et al.1992).

##### **KE1:**

Dose-dependent interference with nuclear translocation of NFAT1 was observed with increasing CNI concentrations from 0.1 nM (Jurkat human T cells) up to 1  $\mu\text{M}$  (1000 nM) using imaging flowcytometry. Higher concentrations induced cellular toxicity and resulted in cell death. Dose-dependent interference of nuclear NFAT1 translocation per CN inhibition was also observed in  $\text{CD4}^{+}$  T cells from healthy donors, again at maximal concentrations of 1  $\mu\text{M}$  with minimum concentration of 10nM (Maguire et al. 2013).

So far, there is no evidence available that the dose response of inhibition of CN phosphatase activity is correlated with nuclear translocation of NFAT; however, the concentration ranges of CNIs for inhibition of CN phosphatase activity and nuclear translocation of NFAT seem to be the same range.

##### **Time-scale**

Inhibition of CN phosphatase activity was examined after 1 hour culture of T cells (Fruman et al.1995, Fruman et al.1992), and inhibition of nuclear translocation of NFAT was measured by imaging flowcytometry after 2 hour culture of T cells with CNI (Maguire et al. 2013).

##### **Known modulating factors**

At present, no evidence is found.

##### **Known Feedforward/Feedback loops influencing this KER**

At present, no evidence is found.

## References

1. Barik, S. (2006). Immunophilins: for the love of proteins. *Cellular and Molecular Life Sciences* 63(24): 2889-900.
2. Bierer, B.E., Holländer, G., Fruman, D. and Burakoff, S.J. (1993). Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. *Current opinion in immunology* 5 (5): 763-73.
3. Bram, R.J., Hung, D.T., Martin, P.K., Schreiber, S.L. and Crabtree, G.R. (1993). Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. *Molecular and cellular biology* 13 (8): 4760-9.
4. Flanagan, W.M., Corthésy, B., Bram, R.J. and Crabtree, G.R. (1991). Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. *Nature* 352 (6338): 803-7.
5. Fruman, D. A., Klee, C. B., Bierer, B. E. and Burakoff, S. J. (1992). Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. *Proceedings of the National Academy of Sciences of the United States of America*. 89(9):3686-90.
6. Fruman, D. A., Bierer, B. E., Benes, J. E., Burakoff, S. J., Austen, K. F. and Katz, H. R. (1995). The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. *Journal of Immunology*. 154(4):1846-51.
7. Hultsch, T., Albers, M. W., Schreiber, S.L. and Hohman, R. J. (1991). Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. *Proceedings of the national academic science of the United States of America*. 14:6229-6233.
8. Kang, C. B., Hong, Y., Dhe-Paganon, S. and Yoon, H. S. (2008). FKBP family proteins: immunophilins with versatile biological functions. *Neurosignals*. 16: 318-325.
9. Kincaid, R. L. (1993). Calmodulin-dependent protein phosphatases from microorganisms to man. A study in structural conservatism and biological diversity. *Adv Second Messenger Phosphoprotein Res*. 27:1-23.
10. Klee, C. B., Draetta, G. F. and Hubbard, M. J. (1988). Calcineurin. *Advances in enzymology and related areas of molecular biology*. 61:149-200.
11. Liu, J., Farmer, J. D. Jr., Lane, W. S., Friedman, J., Weissman, I. and Schreiber, S. L. (1991). Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell*. 66(4): 807-815.
12. Liu, J., Albers, M. W., Wandless, T. J., Luan, S., Alber, D. G., Belshaw, P. J., Cohen, P., MacKintosh, C., Klee, C. B. and Schreiber, S.L. (1992). Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. *Biochemistry*. 31(16):3896-901.
13. Liu, J. (1993). FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. *Immunology today*. 14(6): 290-305.
14. Maguire O, Tornatore KM, O'Loughlin KL, Venuto RC and Minderman H. (2013) Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. *Cytometry A*. 83(12):1096-104.
15. Matsuda, S., Koyasu, S. (2000). A second target of cyclosporin A and FK506. *Tanpakushitsu kakusan koso*. 45(11): 1823-1831.
16. Panhans-Gross, A., Novak, N., Kraft, S. and Bieber, T. (2001). Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). *Journal of Allergy and Clinical Immunology* 107(2): 345-52.
17. Rao, A., Luo, C. and Hogan, PG. (1997). Transcription factors of the NFAT family: regulation and function. *Annual Review of Immunology* 15: 707-47.
18. Schreiber, S.L. and Crabtree, G.R. (1992). The mechanism of action of cyclosporin A and FK506. *Immunology Today* 13(4): 136-42.

19. Siekierka, JJ., Hung, SH., Poe, M., Lin, CS. and Sigal, NH. (1989). A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. *Nature* 341(6244): 755-57.
20. Siekierka, JJ., Wiederrecht, G., Greulich, H., Boulton, D., Hung, SH., Cryan, J., Hodges, PJ. and Sigal, NH. (1990). The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. *Journal of Biological Chemistry* 265(34): 21011-5.
21. Wang, P. and Heitman, J. (2005) The cyclophilins. *Genome Biology* 6 (7):226.
22. Zhang, B.W., Zimmer, G., Chen, J., Ladd, D., Li, E., Alt, F.W., Wiederrecht, G., Cryan, J., O'Neill, E.A., Seidman, C.E., Abbas, A.K. and Seidman, J.G. (1996). T cell responses in calcineurin A alpha-deficient mice. *Journal of experimental medicine* 183(2): 413-20.
23. Zhu, J. and McKeon, F. (1999). NF-AT activation requires suppression of Crm1-dependent export by calcineurin. *Nature*. 398(6724): 256-60.

**Relationship: 1017: Interference, nuclear localization of NFAT leads to Reduction, NFAT/AP-1 complex formation (<https://aopwiki.org/relationships/1017>)**

AOPs Referencing Relationship

| AOP Name   | Adjacency | Weight of Evidence | Quantitative Understanding |
|--|-----------|--------------------|----------------------------|
| Inhibition of Calcineurin Activity Leading to Impaired T-Cell DependentAntibody Response ( <a href="https://aopwiki.org/aops/154">https://aopwiki.org/aops/154</a> ) | adjacent  | High               | High                       |

### *Evidence Supporting Applicability of this Relationship*

#### Taxonomic Applicability

| Term         | Scientific Term | Evidence | Links  |
|--------------|-----------------|----------|--|
| Homo sapiens | Homo sapiens    | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> )   |
| Mus musculus | Mus musculus    | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090</a> ) |

#### Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

#### Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific |          |

NFAT expresses in B cells, mast cells, neutrophils, granulocytes, dendritic cells, macrophages, and natural killer cells as well as T cells from humans, rodents, and other mammalian species (Rao et al. 1997).

CN-NFAT system functionality is common among mammalian species, including humans and rodents. It is also possible that FK506-induced interference with NFAT/AP-1 complex formation at the promoter site of the IL-2 gene is common among mammalian T cells, including those of humans and rodents (Flanagan et al. 1991).

### *Key Event Relationship Description*

Activated (dephosphorylated) nuclear factor of activated T cells (NFAT) is translocated into the nucleus through the molecular changes of exposing nuclear localization signal (NLS) and concomitant masking of nuclear export signal (NES) due to dephosphorylation of the SP motifs of NFAT. (Matsuda and Koyasu 2000, Zhu and McKeon 1999).

In the nucleus NFAT binds with AP 1 at the IL-2 promoter region, (Schreiber and Crabtree 1992; Jain et al. 1992) and induces transcription of IL-2 (Jain et al. 1993). In addition to IL-2, NFAT localized in the nucleus of T cells also binds to the promoter region of the other classes of cytokines including IL-4 and IL-13.

Once CN phosphatase activity is inhibited, dephosphorylation of NFAT and subsequent nuclear localization of NFAT decreases, which results in a decrease of NFAT/AP-1 complex formation at the cytokine promoter sites (Rao et al. 1997).

### *Evidence Supporting this KER*

#### **Biological Plausibility**

As has been mentioned, NFAT has NLS and NES domains among and adjacent to the N-terminal region rich in SP motifs, and once the SP region is dephosphorylated, the NLS domain is exposed whereas the NES domain is covered, which leads to translocation of NFAT into the nucleus (Matsuda and Koyasu 2000).

It is well known from the experiments using CN inhibitors (CNIs) that interference with the nuclear localization of NFAT in T cells leads to a reduction in the formation of NFAT/AP-1 complexes, thereby suppressing transcription of IL-2, IL-4, and a number of other cytokines (Maguire et al. 2013, Jain et al. 1992, Jain et al. 1993).

In contrast to T cells, B-cell receptor-mediated increases in intracellular concentration of calcium in B cells leads to NFAT nuclear localization, thereby producing some classes of cytokines in the same manner as T-cells (Bhattacharyya et al. 2011). However, there has been no report of any evidence that CNI acts directly on B cells to effect antibody production.



Expression of IL-2 receptors in dendritic cells and NKT cells is also reported to be regulated by this CN-NFAT system (Panhans-Gross A et al. 2001; Kim et al. 2010), but there is no report showing that CNIs suppress TDAR through the changes in IL-2R expression in these cells.

## **Empirical Evidence**

The relationship of nuclear localization of NFAT leading to reduced NFAT/AP-1 complex formation bound at the promoter sites of cytokine genes in the presence of CNIs is well known as mentioned above.

Imaging flowcytometry revealed that concentration-dependent reduction of in vitro nuclear localization of NFAT was evident at the maximum concentration of 1  $\mu$ M with minimal concentration of 0.1nM (Jurkat human T cell line) or 10nM (CD4+T cells from whole blood) after 2 hours treatment of tacrolimus (Maguire et al. 2013).

Gel mobility shift assays using Ar-5 human T cells stimulated with cross-linked anti-CD3 antibody showed that NFAT/AP-1 (cFos and Jun) complexes were found only in the nuclear extract with preexisting NFAT in the cytoplasm after T cell stimulation and that the NFAT/AP-1 complexes in the nucleus decreased after 2 hours treatment with CsA at 1 $\mu$ M (Jain et al. 1992). Decreased NFAT translocated to the nucleus, induced by FK506 at 100ng/mL (124nM) or CsA at 500ng/mL (416nM) after 2 hours treatment, hinders the formation of the functional NFAT/AP-1 complexes necessary to binding at the site of IL-2 promoters (Flanagan et al. 1991) NFAT/AP-1 complex formation was also reported to be inhibited by CNI (Rao et al. 1997).

Quantitative understanding of NFAT/AP-1 complex formation in the nucleus is insufficient although nuclear NFAT/AP-1 complex formation was shown to be inhibited by FK506 at concentrations within the range of FK506 for the inhibition of nuclear translocation of NFAT.

## **Uncertainties and Inconsistencies**

Nothing especially

### *Quantitative Understanding of the Linkage*

#### **Response-response relationship**

The relationship of the interference of nuclear localization of NFAT leading to reduced NFAT/AP-1 complex formation bound at the promoter sites of cytokine genes in the presence of CNIs is well known as mentioned above.

#### **KE1:**

Dose-dependent interference with nuclear translocation of NFAT1 was observed with increasing FK506 concentrations from 0.01nM (Jarkat T cells) up to 1  $\mu$ M (1000 nM). Higher concentrations induced cellular toxicity and resulted in cell death. Dose-dependent interference of nuclear NFAT1 translocation per CN inhibition was also observed in CD4+ T cells from healthy donors, again from 10nM to maximal concentrations of 1  $\mu$ M (Maguire et al. 2013). Both parameters were measured after 2 hour culture of T cells with FK506.

#### **KE2:**

Reduction in generation of NFAT/AP-1 complexes can be detected using a gel shift assay (Rao et al. 1997, Jain et al. 1992, Jain et al. 1993).

Decreased NFAT translocated to the nucleus, induced by FK506 at 100ng/mL (124nM) or CsA at 500ng/mL (416nM) after 2 hours treatment, hinders the formation of the functional NFAT/AP-1 complexes necessary to binding at the site of IL-2 promoters (Flanagan et al. 1991). As mentioned above, gel mobility shift assays also showed that NFAT/AP-1 complexes were formed only in the nucleus after T cell activation with unchanged preexisting NFAT in the cytoplasm and that treatment of T cells with 1 $\mu$ M FK506 led to decrease the levels of NFAT/AP-1 complex (Jain et al. 1992).

These findings suggest that nuclear translocation of NFAT after T cell stimulation is strongly related to the complex formation with AP-1 in the nucleus, and FK506 was shown to inhibit NFAT/AP-1 complex formation in

the nucleus at the concentrations within the concentration range of FK506 for suppressing nuclear translocation of NFAT (Maguire et al. 2013).

### **Time-scale**

Nuclear translocation of NFAT was shown to be inhibited in vitro using imaging flowcytometry after 2 hours culture of T cells with FK506 (Maguire et al. 2013), and gel mobility shift assays revealed the inhibition of nuclear translocation of NFAT and following complex formation with AP-1 within the nucleus after 2 hours culture of T cells with FK506 (Jain et al. 1992, Flanagan et al. 1991).

### **Known modulating factors**

At present, no evidence is found.

### **Known Feedforward/Feedback loops influencing this KER**

At present, no evidence is found.

### **References**

1. Bhattacharyya, S., Deb, J., Patra, A.K., Thuy Pham, D.A., Chen, W., Vaeth, M., Berberich-Siebelt, F., Klein-Hessling, S., Lamperti, E.D., Reifenberg, K., Jellusova, J., Schweizer, A., Nitschke, L., Leich, E., Rosenwald, A., Brunner, C., Engelmann, S., Bommhardt, U., Avots, A., Müller, M.R., Kondo, E. and Serfling, E. (2011). NFATc1 affects mouse splenic B cell function by controlling the calcineurin-NFAT signaling network. *The Journal of experimental medicine* 208 (4): 823-39.
2. Flanagan, W.M., Corthésy, B., Bram, R.J. and Crabtree, G.R. (1991). Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. *Nature* 352 (6338): 803-7.
3. Jain, J., McCaffrey, P. G., Valge-Archer, V. E. and Rao, A. (1992). Nuclear factor of activated T cells contains Fos and Jun. *Nature*. 356(6372): 801-4.
4. Jain, J., Miner, Z. and Rao, A. (1993). Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. *Journal of immunology*. 151(2): 837-48.
5. Kim, T., Kim, N. and Kang, H. J. (2010). FK506 causes cellular and functional defects in human natural killer cells. *Journal of leukocyte biology*. 88:1089-1097.
6. Maguire O, Tornatore KM, O'Loughlin KL, Venuto RC and Minderman H. (2013) Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. *Cytometry A*. 83(12):1096-104.
7. Matsuda, S., Koyasu, S. (2000). A second target of cyclosporin A and FK506. *Tanpakushitsu kakusan koso*. 45(11): 1823-31.
8. Panhans-Gross, A., Novak, N., Kraft, S., and Bieber, T. (2001). Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). *Journal of Allergy and Clinical Immunology* 107(2): 345-52.
9. Rao, A., Luo, C., and Hogan, PG. (1997). Transcription factors of the NFAT family: regulation and function. *Annual Review of Immunology* 15: 707-47.
10. Schreiber, SL., and Crabtree, GR. (1992). The mechanism of action of cyclosporin A and FK506. *Immunology Today* 13(4): 136-42.
11. Zhu, J. and McKeon, F. (1999). NF-AT activation requires suppression of Crm1-dependent export by calcineurin. *Nature*. 398(6724): 256-60.

**Relationship: 1509: Reduction, NFAT/AP-1 complex formation leads to Suppression, IL-2 and IL-4 production(<https://aopwiki.org/relationships/1509>)**

AOPs Referencing Relationship

| AOP Name  | Adjacency | Weight of Evidence | Quantitative Understanding |
|---|-----------|--------------------|----------------------------|
| Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response ( <a href="https://aopwiki.org/aops/154">https://aopwiki.org/aops/154</a> ) | adjacent  | High               | High                       |

***Evidence Supporting Applicability of this Relationship***

Taxonomic Applicability

| Term         | Scientific Term | Evidence | Links  |
|--------------|-----------------|----------|--|
| Homo sapiens | Homo sapiens    | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> ) |

Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

In purified T cell from male C57BL/6J mice, T-5224 (a selective c-Fos/AP-1 inhibitor) inhibits the DNA-binding activity of AP-1, IL-2 production and CD25 (IL-2R) up-regulation (Yoshida et al. 2015).

In splenic lymphocytes and/or CD4<sup>+</sup> T cells, ursolic acid suppressed products of NF- $\kappa$ B, NFAT and AP-1, and inhibits secretion of IL-2 and IL-4, mRNA level of IL-2 and CD25 expression (Checker et al. 2012).

NFATp- and NFAT4-deficient mice indicate decreased production of IL-2 (Ranger et al. 1998).

NFAT/AP-1 complex formation in the nucleus was shown using murine and human T cells lines (Jain J et al. 1992). In addition to data on suppression of cytokine production by CNI in rodents, FK506 is reported to inhibit expression of both IL-2 and mRNA in human anti-CD3/PMA-activated cells (Dumont et al. 1998).

***Key Event Relationship Description***

Localized nuclear factor of activated T cells (NFAT) in the nucleus of T cells forms complexes with activator protein-1 (AP-1) at the Interleukin (IL)-2 promoter region (Schreiber and Crabtree 1992; Jain et al. 1992), which induces transcription of IL-2 (Jain et al. 1993). In addition to IL-2, NFAT localized in the nucleus of T cells also binds to the promoter region of the other classes of cytokines including IL-4 and IL-13.

For IL-2, NFAT proteins are necessary for IL-2 gene expression and interaction of NFAT with AP-1 is required for IL-2 gene transcription. For IL-4, At least five different NFAT sites have been described in the IL-4 promoter with at least three of them being composite sites binding NFAT and AP-1 (Macián et al. 2001).

Lowered nuclear localization of NFAT by calcineurin inhibitor (CNI) results in decreased formation of NFAT/AP-1 complex at the promoter region of IL-2 genes in the nucleus of T cells thereby reducing the transcription of IL-2 (Dumont et al. 1998). Production in T cells of IL-4 and other classes of cytokines is also suppressed in the same manner as IL-2 (Dumont et al. 1998).

### *Evidence Supporting this KER*

#### **Biological Plausibility**

T-5224, a selective c-Fos/AP-1 inhibitor, inhibits the DNA-binding activity of AP-1 in primary murine T cells. T-5224 also inhibits CD25 (one of IL-2 receptors) up-regulation, IL-2 production, and c-Fos DNA-binding activity in mice (Yoshida et al. 2015).

Dexamethasone represses the IL-2 mRNA induction. glucocorticoid-induced leucine zipper (GILZ) is one of the most prominent glucocorticoid-induced genes, and inhibited the induction of the NFAT reporter and interferes with the AP-1 component of the NFAT/AP-1 complex. GILZ also inhibits the IL-2 promoter (Mittelstadt et al. 2001).

Ursolic acid suppressed activation of three immunoregulatory transcription factors NF- $\kappa$ B, NFAT and AP-1. Treatment of lymphocytes and CD4<sup>+</sup> T cells with ursolic acid inhibited secretion of IL-2 and IL-4 cytokines. Treatment of CD4<sup>+</sup> T cells with ursolic acid suppressed mRNA level of IL-2. Treatment of lymphocytes with ursolic acid inhibited the upregulation of CD25 expression on T cells (Checker et al. 2012).

NFATp- and NFAT4-deficient mice indicate decreased production of Th1 cytokine including IL-2 (Ranger et al. 1998).

It is generally accepted that NFAT, translocated to the nucleus after T-cell stimulation, binds with AP-1 to the promoter regions of the cytokine genes to mount transcription, which follows production of these T-cell-derived cytokines. Of these cytokines, IL-2 and IL-4 promote proliferation, maturation, and class-switching of B cells to enhance TDAR.

There is also sufficient evidence to support the hypothesis that CNI-induced decreases in T-cell-derived cytokine production is mediated through suppressed nuclear localization of NFAT, with a resultant decrease in the amount of NFAT/AP-1 complex binding to the promoter regions of T-cell-derived cytokines.

When stimulated with ovalbumin, calcineurin A (CnA)-knockout (KO) mice produce less Interferon (IFN)- $\gamma$ , IL-2, and IL-4 than wild-type mice. However, primary antibody response in CnA-KO mice is normal in response to trinitrophenol-ovalbumin (Zhang et al. 1996).

The following phenotypes are observed in NFAT-KO mice: moderate hyperproliferation with splenomegaly; moderately enhanced B- and T-cell responses, with bias towards Th2- cell responses; decreased IFN- $\gamma$  production in response to TCR ligation; reduced proliferative responses by T cells; impaired repopulation of the thymus and lymphoid organs; impaired Th2-cell responses and IL-4 production; grossly impaired T-cell effector functions, with profound defects in cytokine production and cytolytic activity; B-cell hyperactivity; impaired development of CD4 and CD8 single-positive cells, with increased apoptosis of double-positive thymocytes; and mild hyperactivation of peripheral T cells (Macian, 2005).

Therefore, the study of NFAT-KO mice shows that NFAT is involved in a wide range of immune responses, and some of these phenomenon are known to be regulated by calcineurin (CN). Suppression of T-cell-derived cytokines is noted both in CnA-KO and NFAT-KO mice, which indicates that the production of T-cell derived cytokines such as IL-2 and IL-4 is regulated by the CN-NFAT system.

FK506-FKBP12 complex decreased CN phosphatase activity, which inhibits. Because NF-ATp is an essential transcription factor regulating the IL-2 gene, FK506 ultimately blocks the T-cell response by inhibiting IL-2 transcription (Panhans-Gross A et al. 2001). FK506 inhibited IL-2 mRNA expression in anti-CD3/phorbol 12-myristate-13-acetate (PMA)-activated cells (Dumont et al. 1998).

These facts indicate that although NFAT is widely involved in the function of T cells, the effect of CNIs is to suppress production of some classes of T cell-derived cytokines through reducing the formation of NFAT/AP-1 complexes induced by inhibition of CN phosphatase activity.

#### **Empirical Evidence**

Empirical support of Reduction, NFAT/AP-1 complex formation leading to Suppression, IL-2 and IL-4 production is strong.

**Rationale:**

- In purified T cell from male C57BL/6J mice, T-5224 (a selective c-Fos/AP-1 inhibitor) inhibits the DNA-binding activity of AP-1 and CD25 (one of IL-2 receptors) up-regulation at 80 µg/mL, and IL-2 production in a dose-dependent manner from 40 to 80 µg/mL (Yoshida et al. 2015).
- In splenic lymphocytes stimulated with concanavalin A for 24 h in C57BL/6 mice, ursolic acid suppressed products of NF-κB, NFAT and AP-1 at 5 µM for 4 h. Secretion of IL-2 and IL-4 was inhibited in lymphocytes stimulated with concanavalin A for 24 h at concentrations of 0.5, 1 and 5 µM of ursolic acid, and lymphocytes and CD4<sup>+</sup> T cells stimulated with anti-CD3/anti-CD28 mAb for 24 h at concentration of 5 µM of ursolic acid. In CD4<sup>+</sup> T cells stimulated with anti-CD3/anti-CD28 mAb for 24 h, ursolic acid suppressed mRNA level of IL-2 at 5 µM for 4 h. In lymphocytes stimulated with concanavalin A for 24 h, ursolic acid inhibited CD25 expression at 5 µM for 4 h (Checker et al. 2012).
- In NFATp- and NFAT4-deficient mice, cultured splenocytes bound anti-CD3 for 48 h indicates decreased production of Th1 cytokine including IL-2 (Ranger et al. 1998).

It is well established that inhibition of NFAT/AP-1 complex formation at the promoter sites reduces the production of T-cell-derived cytokines including IL-2 and IL-4, which are mainly involved in T-cell-dependent antibody response.

- NFAT/AP-1 complex formation is inhibited by CNIs shown by gel shift mobility assay using human T cell line or CD4<sup>+</sup> T cells from healthy donors after 2 hours treatment with cyclosporin A (CsA) at 1 µM. Preceding NFAT nuclear localization after T cell activation is suppressed with FK506 at the dose range of 0.01 nM (Jarkat T cells) or 10 nM (CD4<sup>+</sup> T cells) to 1 µM (Maguire et al. 2013), and NFAT nuclear localization and NFAT/AP-1 complex formation is shown to be strongly related (Jain et al. 1992, Jain et al. 1993).
- In CD3/PMA-activated human T cells, FK506 suppressed production of IL-2, IL-4, and IFN-γ at the concentrations of 1.2 to 12.5 nM after 22 to 24 hours culture as well as inhibited expression of IL-2, IL-4, and IFN-γ mRNA in a dose-dependent (10 nM) manner after 3 day culture (Dumont et al. 1998).
- Treatment with CsA completely eliminated detectable IL-2 release from 3A9 T cells co-cultured with antigen-bearing Ch27 B cells with an IC<sub>25</sub> and IC<sub>50</sub> for IL-2 production of 1.19 nM and 1.99 nM. Treatment with other immunosuppressant compounds (dexamethasone, azathioprine, methotrexate, benzo(a)pyrene and urethane) also resulted in decreased IL-2 release from stimulated 3A9 T cells at non-cytotoxic concentrations. Urethane, a weakly immunosuppressive chemical, was least potent in the assay, with an IC<sub>25</sub> and IC<sub>50</sub> for IL-2 secretion of 4.24 mM and 13.26 mM (D.M. Lehmann. et al. 2018).
- In female B6C3F1 mice, 1,2:5,6-dibenzanthracene exposure reduced production of IL-2 in spleen cell culture supernatants after in vitro stimulation with Concanavalin A or lipopolysaccharide (Donna, C. et al. 2010).
- Treatment with CsA at 50 mg/kg BID via oral gavage or 2C1.1 (a fully human anti-ORAI1 monoclonal antibody) at 25 mg/kg single IV resulted in reduction of IL-2, IL-4, IL-5, and IL-17 cytokine production from PMA/ionomycin stimulation of whole blood in the cynomolgus monkey (Kevin, G. et al. 2014).
- In male CD-1 mice, chronic psychosocial stress (types of social outcome occurred: residents becoming subordinates) reduced IL-2 release in response to keyhole limpet hemocyanine (Alessandro, B. et al. 2003).

Reduced nuclear translocation of NFAT followed by NFAT/AP-1 complex formation and suppression of IL-2/IL-4 productions are shown to occur under similar dose ranges and treatment duration.

## Uncertainties and Inconsistencies

CNIs are reported to suppress IL-17 release from Th17 cells and development of Th17 cells from naïve T cells (Tsuda et al, 2012). On the other hand, Yadav reported that Th17 cells increased and Treg cells decreased in number and that the levels of RORC mRNA increased and those of FOXP3 decreased in renal transplanted patients with chronic calcineurin inhibitor toxicity (Yadav, 2015). From these findings, CNIs suppress the functions of Th17 and Treg cells, which enhance Th17 cells to develop chronic CNI toxicity.

FK506 suppresses expression of IL-2 receptor (IL-2R: CD25) and costimulatory molecules CD80 (B7.1)/CD40 in Langerhans cells (Panhans-Gross A et al. 2001).

In human NK cells, FK506 suppresses IL-2 responsive proliferation and cytokine production as well as lowers cytotoxicity directed toward K562 tumor cells (Kim et al. 2010). FK506 suppresses IL-2 production of NKT cell line DN32.D3 induced by stimulus from PMA/calcium -ionophore (van Dieren et al. 2010).

The relationship between these FK506-induced mechanisms and NFAT and contribution of those to TDAR are unclear.

In addition to NFAT/AP-1 complexes, NFAT forms complexes at the site of IL-3 and IL-4 enhancers with avian musculoaponeurotic fibrosarcoma oncogene homolog, early growth response 1, early growth response 4, interferon-regulatory factor 4, octamer-binding transcription factor, and other transcriptional partners to induce transcription of a variety of cytokines (Macian 2005). The production of cytokine induced by these transcriptional partners also suppressed by CNI; however, contribution of these additional transcription factors to TDAR is also unclear.

## *Quantitative Understanding of the Linkage*

### Response-response relationship

In purified T cells from male C57BL/6J mice, T-5224 (a selective c-Fos/AP-1 inhibitor) inhibits the DNA-binding activity of AP-1 at 80 µg/mL. On the other hand, T-5224 inhibits IL-2 production in a dose-dependent manner from 40, 60 and 80 µg/mL after 48 hours culture. T-5224 also inhibits CD25 (IL-2R) up-regulation at 80 µg/mL (Yoshida et al. 2015).

In splenic lymphocytes stimulated with concanavalin A for 24 h in C57BL/6 mice, ursolic acid suppressed products of NF-κB, NFAT and AP-1 at 5 µM. In lymphocytes stimulated with concanavalin A for 24 h, ursolic acid inhibits secretion of IL-2 and IL-4 at 0.5, 1 and 5 µM. In lymphocytes and CD4<sup>+</sup> T cells stimulated with anti-CD3/anti-CD28 mAb for 24 h, ursolic acid also inhibits secretion of IL-2 and IL-4 at 5 µM. In CD4<sup>+</sup> T cells stimulated with anti-CD3/anti-CD28 mAb for 24 h, ursolic acid suppressed mRNA level of IL-2 at 5 µM. In lymphocytes stimulated with concanavalin A for 24 h, ursolic acid inhibited CD25 expression at 5 µM (Checker et al. 2012).

These findings showed that T-5244 and ursolic acid treated for 24 hours inhibit NFAT/AP-1 complex formation at a single concentration each and that these compounds suppress IL-2 and IL-4 production with dose dependent manner including the doses for inhibition of NFAT/AP-1 complex formation.

FK506 suppressed proliferation in human T cells induced by anti-CD3 mAb in the presence of adherent autologous peripheral blood mononuclear cells (mean IC<sub>50</sub> = 0.06 nM). FK506 suppressed, in a dose-dependent (1.2 to 12.5 nM) manner after 22-24 hours culture, production of IL-2, IL-4, and IFN-γ by human T cells stimulated with anti-CD3 mAb in the presence of PMA, as well as inhibited, also in a dose-dependent (10 nM) manner, expression of IL-2, IL-4, and IFN-γ mRNA in anti-CD3/PMA- activated cells (Dumont et al. 1998). On the other hand, the quantitative data for the decreased formation of NFAT/AP-1 complexes by CNI is insufficient, although the formation was suppressed by FK506 at the concentration within the range needed for suppressed production of IL2/IL-4 by FK506 after 2 hours culture.

### Time-scale

Inhibition of NFAT/AP-1 complex is detected by gel mobility shift assay after 2 hours culture with CNI; however, suppression of IL2/IL-4 could be measured after 22-48 hours in vitro culture.

## Known modulating factors

At present, no evidence is found.

## Known Feedforward/Feedback loops influencing this KER

At present, no evidence is found.

## References

1. Schreiber, SL., and Crabtree, GR. (1992). The mechanism of action of cyclosporin A and FK506. *Immunology Today* 13(4): 136-42.
2. Jain J., McCaffrey P.G., Valge-Archer V.E., Roa A.(1992). Nuclear factor of activated T cells contains Fos and Jun. *Nature* 356(6372):801-804.
3. Jain J., Miner Z., Rao A. (1993). Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. *Journal of Immunology* 151(2): 837-848.
4. Macián, F., López-Rodríguez, C. and Rao, A. (2001). Partners in transcription: NFAT and AP-1. *Oncogene*. 20(19): 2476-89.
5. Yoshida, T., Yamashita, K., Watanabe, M., Koshizuka, Y., Kuraya, D., Ogura, M., Asahi, Y., Ono, H., Emoto, S., Mizukami, T., Kobayashi, N., Shibasaki, S., Tomaru, U., Kamachi, H., Matsushita, M., Shiozawa, S., Hirono, S. and Todo, S. (2015). The Impact of c- Fos/Activator Protein-1 Inhibition on Allogeneic Pancreatic Islet Transplantation. *Am J Transplant*. 15(10): 2565-75.
6. Mittelstadt, PR. and Ashwell, JD. (2001). Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. *J Biol Chem*. 276(31):29603-10.
7. Checker, R., Sandur, SK., Sharma, D., Patwardhan, RS., Jayakumar, S., Kohli, V., Sethi, G., Aggarwal, BB. and Sainis, KB. (2012). Potent Anti-Inflammatory Activity of Ursolic Acid, a Triterpenoid Antioxidant, Is Mediated through Suppression of NF- $\kappa$ B, AP-1 and NF-AT PLoS One. 7(2): e31318.
8. Ranger, AM., Oukka, M., Rengarajan, J. and Glimcher, LH. (1998). Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. *Immunity*. 9(5):627-35.
9. Dumont, F.J., Staruch, M.J., Fischer, P., DaSilva, C. and Camacho, R. (1998). Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. *Journal of immunology* 160 (6): 2579-89.
10. Macian, F. (2005) NFAT proteins: key regulators of T-cell development and function. *Nat Rev Immunol*. 5(6): 472-84.
11. Panhans-Gross, A., Novak, N., Kraft, S., and Bieber, T. (2001). Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). *Journal of Allergy and Clinical Immunology* 107(2): 345-52.
12. van Dieren, J.M., Lambers, M.E.H., Kuipers, E.J., Samsom, J.N., van der Woude, C.J. and Nieuwenhuis, E.E.S. (2010). Local immune regulation of mucosal inflammation by tacrolimus. *Digestive diseases and sciences* 55(9): 2514-19.
13. Zhang, BW., Zimmer, G., Chen, J., Ladd, D., Li, E., Alt, FW., Wiederrecht, G., Cryan, J., O'Neill, EA., Seidman, CE., Abbas, AK., Seidman, JG. (1996). T cell responses in calcineurin A alpha-deficient mice. *J Exp Med*. 183(2): 413-20.
14. Alessandro B, Paola S, Alberto E. Paneraic, Tiziana P, Paola Palanzaa and Stefano P(2003). Chronic psychosocial stress-induced down- regulation of immunity depends upon individual factors *Journal of Neuroimmunology* 141: 58–64
15. Donna C. S, Matthew J. S and Kimber L. W Jr. (2010) Systemic immunosuppression following a single pharyngeal aspiration of 1,2:5,6-dibenzanthracene in female B6C3F1 mice, *Journal of Immunotoxicology*, 7:3, 219-231
16. Kevin G, Hossein S, Raju S, Valerie A, Anna K, Ming Z, Fen-Fen L, Hung Q. N, Lei Z, John K. S, Min W and Helen J. M(2015) Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkey, *Journal of Immunotoxicology*, 12:2, 164-173,

17. D.M. Lehmann, W.C. Williams.(2018) Development and Utilization of a Unique In Vitro Antigen Presentation Co-culture Model for Detection of Immunomodulating Substances. *Toxicol In Vitro*.53: 20–28.



**Relationship: 1510: Suppression, IL-2 and IL-4 production leads to Impairment, T-cell dependent antibody response(<https://aopwiki.org/relationships/1510>)**

AOPs Referencing Relationship

| AOP Name  | Adjacency | Weight of Evidence | Quantitative Understanding |
|---|-----------|--------------------|----------------------------|
| Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response ( <a href="https://aopwiki.org/aops/154">https://aopwiki.org/aops/154</a> ) | adjacent  | High               | High                       |

*Evidence Supporting Applicability of this Relationship*

Taxonomic Applicability

| Term              | Scientific Term     | Evidence | Links  |
|-------------------|---------------------|----------|--|
| Homo sapiens      | Homo sapiens        | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606</a> )   |
| Mus musculus      | Mus musculus        | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090</a> ) |
| cynomolgus monkey | Macaca fascicularis | High     | NCBI ( <a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9541">http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9541</a> )   |

Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

In cynomolgus monkeys, the effects of CsA on production of IL-2 and IL-4, and antigen-specific IgM and IgG in TDAR were demonstrated (Gaida K. 2015).

Suppressed IgE and antigen specific IgG1 productions by the blocking of IL-4 receptor were reported in mice using dupilumab (anti-IL-4/13R antibody) (Sanofi K.K. 2018).

Suppressed antigen specific IgE production by the inhibition of IL-4 production was reported in mice using suplatast tosilate (Taiho Pharmaceutical 2013).

Suppressed antigen specific IgE and IL-4 productions by the inhibition of IL-4 production were reported in human cell culture using suplatast tosilate(Taiho Pharmaceutical 2013).

The effects of FK506 on serum concentration of anti-KLH antibodies IgM and IgG have been demonstrated in rats treated with FK506 for over four weeks and immunized with KLH (Ulrich et al. 2004). The effects of FK506 and CsA on antigen-specific plaque-forming splenocytes have been demonstrated in mice treated with FK506 or CsA for 4 days and immunized with SRBC (Kino et al. 1987b).

The effects of FK506 and CsA on the levels of IgM and IgG in the culture supernatant have been demonstrated in human cells (Heidt et al, 2009, Sakuma et al, 2001).

The effects of FK506 and CsA on production of IL-2 and IL-4 have been demonstrated using mice and human cells (Kino et al. 1987a, Dumont et al. 1998).

These facts suggest that there are no species differences between humans, monkeys and rodents in inhibitions of IL-2 and IL-4 production and TDAR induction.

### ***Key Event Relationship Description***

Interleukin (IL)-2 and IL-4 are produced and secreted by helper T cells and play important roles in the development of T-cell dependent antibody response (TDAR), both of which induces/enhances T cell dependent antibody production. IL-4 affects maturation and class switching of B cells as well as proliferation, IL-2 promotes differentiation of B cells through IL-2 receptors and stimulates the activated T cell into T cell called Th2 cell. Therefore, suppressed production of IL-2 and IL-4 impairs T cell dependent antibody production (Alberts et al. 2008).

T cells, B cells, and antigen-presenting cells such as dendritic cells are involved in inducing and developing of TDAR. Thus, changes in any of these immune cell populations can influence TDAR

T cell-derived cytokines play important roles in the development of TDAR. Among them, IL-2 promotes proliferation of B cells, and IL-4 affects maturation and class switching of B cells as well as proliferation, both of which induces/enhances T cell dependent antibody production.

Thus, suppressing the production of IL-2, IL-4, and other cytokines in T cells reduces stimulation of B cells including proliferation, activation, and class switching, and leading to impairment of TDAR. Therefore, suppressing the production of these B-cell-related cytokines appears to be the main factor in impairment of TDAR by inhibitors of T-cell-dependent-antibody production.

### ***Evidence Supporting this KER***

#### **Biological Plausibility**

Cyclosporin A (CsA) is known to be one of the calcineurin inhibitors. CsA-treatment is reported to suppress the productions of IL-2 and IL-4 and result in the reduction of the productions of antigen-specific IgM and IgG in cynomolgus monkeys (Gaida K. 2015).

It is established that IL-2 stimulates B cells to proliferate through the surface IL-2 receptors and that IL-4 stimulates B cells to proliferate, to induce class switch, and to differentiate into plasma and memory cells.

Dupilumab is known as anti-IL-4/13 receptor (IL-4/13R) antibody. Dupilumab (Dupixent) reduces productions of immunoglobulin (Ig) E and antigen specific IgG1 in mice (Sanofi K.K. 2018). It suggests that the blocking of IL-4 signaling by anti-IL-4/13R antibody results in the decrease in T cell dependent antibody production.

Th2 cell produces cytokines including IL-4. Suplatast tosilate (IPD) is known as an inhibitor of the production of IL-4 and IL-5 from Th2 cells and reduces the production of antigen specific IgE in human cell culture and mice (Taiho Pharmaceutical 2013). These findings suggests that the reduction of IL-4 production by the inhibitor of Th2 cell cytokines results in reduced production of IgE and/or IgG1 through inhibitions of maturation, proliferation and class switching of B cells.

IL-2 binds to IL-2 receptor (IL-2R) and acts on T cell. CD25 is one of IL-2R. Basiliximab (Simulect) is known as anti-CD25 antibody. Basiliximab binds to IL-2R and blocks IL-2 signaling. Clinical transplantation study of basiliximab reveals decreases in rejections. On the other hand, basiliximab inhibits the activation of antigen specific T cells (Novartis Pharma 2016). They suggest that the blocking of IL-2 signaling by anti-IL-2R antibody results in decreased rejection through the inhibition of the activation of antigen specific T cell with reduced antibody production.

FK506 and CsA suppress mRNA expression levels of cytokines in T cells including IL-2 and IL-4 that stimulate proliferation of B cells as well as B cell activation and class switching (Heidt et al, 2010).

Several in vivo studies in rodents showed decreased TDAR by the treatment of FK506 (Kino et al. 1987b, Ulrich et al. 2004). In in vitro tests examining antibody production in blood samples obtained from blood-bank donors, peripheral blood mononuclear cells (PBMC) treated with FK506 and CsA suppressed the production of IgM and IgG antibodies to T-cell dependent antigens (Heidt et al, 2009).

T cells, B cells, and antigen-presenting cells such as dendritic cells are involved in inducing and developing of TDAR. Thus, changes in any of these immune cell populations can influence TDAR.

However, as for the suppression of humoral immunity induced by the inhibition of calcineurin (CN) phosphatase activity, calcineurin inhibitors (CNIs) do not affect B cells directly but rather indirectly through T cells. That is, FK506 and CsA are capable of inhibiting immunoglobulin production when B cells are cultured with non-pre-activated T cells, but FK506 and CsA fail to inhibit immunoglobulin levels when pre-activated T cells are used to stimulate B cells. Hence, the inhibition of B cell response by FK506 and CsA appears due solely to inhibition of T helper cells (Heidt et al, 2010).

Therefore, it is concluded that decreased amounts of IL-2 and IL-4 secreted from helper T cells is the main factor for suppression of TDAR induced by CN phosphatase inhibition.

## **Empirical Evidence**

Empirical support of the suppression, IL-2 and IL-4 production leads to impairment, T-cell dependent antibody response is strong.

Rationale:

- Cynomolgus monkeys treated with CsA at 50 mg/kg BID for 24 days suppression of IL-2, IL-4 and sheep red blood cell (SRBC)-specific IgM and IgG (Gaida K. 2015).
- In the allergen-induced pneumonia model in mice, dupilumab (anti-IL-4/13R antibody) reduced productions of IgE and antigen specific IgG1 at 25 mg/kg of twice weekly subcutaneous administration for 4 weeks (Sanofi K.K. 2018).
- In mice immunized with dinitrophenyl antigen by i.p. injection, suplatast tosilate (an inhibitor of the production of cytokines on Th2 cell) reduced productions of antigen specific IgE at 10, 20, 50 and 100 mg/kg of oral administration for 5 days (Taiho Pharmaceutical 2013). In human cell culture immunized with Japanese cedar antigen, suplatast tosilate reduced productions of antigen specific IgE at the concentration of 10 µg/mL for 10 days (Taiho Pharmaceutical 2013).
- In the clinical study of renal transplantation, basiliximab decreased incidence of acute rejection at 20 mg/kg (Novartis Pharma 2016). In human T cell culture immunized with PPD, basiliximab reduced activation of antigen specific T cell at the concentration of 300 ng/mL (Novartis Pharma 2016).
- In CD3/phorbol 12-myristate-13-acetate-activated human T cells, FK506 suppressed production of IL-2, IL-4 and Interferon (IFN)-γ at the concentrations of 1.2 to 12.5 nM as well as inhibited expression of IL-2, IL-4 and IFN-γ mRNA at the concentrations of 10 nM. (Dumont et al. 1998).
- FK506 or CsA suppressed production of IL-2 in mouse mixed lymphocyte reaction (MLR) at 0.1 to 10 nM of FK506 and 10 to 100 nM of CsA as well as in human MLR at 0.1 to 10 nM of FK506 and 10 to 100 nM of CsA (Kino et al. 1987a).
- After 9-day culture of B cells and non-pre-activated T cell stimulation with FK506 or CsA, the levels of IgM and IgG in the culture supernatant were reduced at 0.3 and 1.0 ng/mL (0.37 and 1.24 nM) of FK506 or 50 and 100 ng/mL (41 and 83 nM) of CsA (Heidt et al, 2009).
- After 4-day culture of SKW6.4 cells (IL-6-dependent IgM-secreting human B-cell line) and anti-CD3/CD28 stimulated PBMC culture supernatant with FK506 or CsA, the level of IgM in the culture

supernatant was reduced at the concentrations of 0.01 to 100 ng/mL (0.01 to 124 nM) of FK506 or 0.1 to 1000 ng/mL (0.08 to 832 nM) of CsA (Sakuma et al, 2001).

- Rats were treated with FK506 for over four weeks and immunized with keyhole limpet hemocyanine (KLH), after which serum concentration of anti-KLH IgM and IgG reduced at the dose levels of 3 mg/kg/day (Ulrich et al. 2004).
- Mice were treated with FK506 or CsA for 4 days, and immunized with sheep red blood cells (SRBC), after which antigen-specific plaque-forming splenocytes reduced at the dose levels of 3.2, 10, 32 and 100 mg/kg of FK506 or 32 and 100 mg/kg of CsA (Kino et al. 1987b).
- 1,2:5,6-dibenzanthracene single administration suppressed production of IL-2 and total IgG antibody in mice at the dose levels of 3 and 30 mg/kg (Donna, C. et al. 2010).
- In male CD-1 mice, chronic psychosocial stress (types of social outcome occurred: residents becoming subordinates) for 21 days reduced IL-2 release in response to KLH and decrease in anti-KLH IgG (Alessandro, B. et al. 2003).

In vitro suppression of T-cell-derived cytokines and T-cell-dependent antibody production or antibody production after polyclonal T-cell stimulation showed similar dose responses to CNIs. Time gaps were found, however, between these two KEs, which showed earlier onset of cytokine production and delayed onset of antibody production.

### **Uncertainties and Inconsistencies**

IL-2 affects multiple populations of immune cells expressing IL-2 receptors, while IL-4 mainly acts on B cells. Therefore, reduced production of both IL-2 and IL-4 might certainly induce suppression of TDAR; however, there remains some possibility of additional suppression of other immune functions.

## ***Quantitative Understanding of the Linkage***

### **Response-response relationship**

Cynomolgus monkeys treated with CsA at 50 mg/kg BID showed suppression of IL-2 and IL-4 production and inhibition of SRBC-specific IgM and IgG in TDAR (Gaida K. 2015).

In the blocking of IL-4 receptor in mice by dupilumab (anti-IL-4/13R antibody) at 25 mg/kg of twice weekly subcutaneous administration for 4 weeks, IgE production was suppressed to about 1/100 and antigen specific IgG1 production was suppressed to about 1/200 (Sanofi K.K. 2018).

In the inhibition of IL-4 production in mice by suplatast tosilate at 10, 20, 50 and 100 mg/kg of oral administration for 5 days, antigen specific IgE production was suppressed from about 1/10 to 1/100 (Taiho Pharmaceutical 2013). In human T cell culture by suplatast tosilate at the concentration of 10 µg/mL, antigen specific IgE production after 10 days was suppressed from 56 to 72% and IL-4 production after 3 days was suppressed from 58 to 76% (Taiho Pharmaceutical 2013).

As for IL-2 and antibody production, in vitro T-cell-induced polyclonal B cell activation to produce antibody was inhibited with anti-IL-2 and anti-IL-2R antibodies. That is, murine small resting B cells, cultured with irradiated hapten-specific TH1 clone, were induced to enter cell cycle at 2 days and to secrete antibody at 5 days. An anti-IL-2 and anti-IL-2R antibodies completely inhibited this T-cell dependent antibody production (Owens T, 1991).

In the human T-B cell co-culture stimulated with anti-CD3 monoclonal antibody, CNIs of FK506 and CsA lowered the m-RNA levels of T-cell cytokines at 8h post-stimulation including IL-2 and IL-4 at 1.0ng/mL (1.24nM) FK506 or 100ng/mL (90.7nM) CsA and inhibited IgM and IgG productions after 9 days at 0.3 and 1.0ng/mL FK506 and 50 and 100ng/mL CsA (Heidt S. 2010).

### **Time-scale**

In CsA-treatment for 24 days at 50 mg/kg BID, cynomolgus monkeys showed suppression of IL-2 and IL-4 production and inhibition of SRBC-specific IgM and IgG in TDAR (Gaida K. 2015).

In human T cell culture, suplatast tosilate inhibits IL-4 production after 3 days and antigen specific IgE production after 10 days (Taiho Pharmaceutical 2013).

In the human T-B cell co-culture, CNIs of FK506 and CsA lowered the m-RNA levels of IL-2 and IL-4 at 8h post-stimulation and inhibited IgM and IgG productions after 9 days (Heidt S. 2010).

### **Known modulating factors**

At present, no evidence is found.

### **Known Feedforward/Feedback loops influencing this KER**

At present, no evidence is found.

## **References**

1. Alberts, B., Johnson, A., Lewis, L., Raff, M., Roberts, K. and Walter, P. (2008). Molecular Biology of the Cell. 5th ed., Garland Science, New York. 1539-1601
2. Sanofi K.K. (2018) Drug interview form Dupixent subcutaneous injection 300 mg syringe. 2nd edition.
3. Taiho Pharmaceutical Co., Ltd. (2013) Drug interview form IPD capsule 50 and 100. Revised 5th edition.
4. Novartis Pharma K.K. (2016). Drug interview form Simulect i.v. injection 20 mg. 10th edition.
5. Dumont, F.J., Staruch, M.J., Fischer, P., DaSilva, C. and Camacho, R. (1998). Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. Journal of immunology 160 (6): 2579-89.
6. Heidt, S., Roelen, D. L., Eijssink, C., Eikmans, M., van Kooten, C., Claas, F. H. and Mulder, A. (2010). Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clinical and experimental immunology. 159(2): 199-207.
7. Gaida K., Salimi-Moosavi H., Subramanian R., Almon V., Knize A., Zhang M., Lin F.F., Nguyen H.Q., Zhou L., Sullivan J.K., Wong M., McBride H.J. (2015). Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkey. J Immunotoxicol 12:164-173.
8. Kino, T., Hatanaka, H., Miyata, S., Inamura, N., Nishiyama, M., Yajima, T., Goto, T., Okuhara, M., Kohsaka, M. and Aoki, H. (1987a). FK- 506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. Journal of antibiotics. 40(9): 1256-1265.
9. Kino, T., Hatanaka, H., Hashimoto, M., Nishiyama, M., Goto, T., Okuhara, M., Kohsaka, M., Aoki, H. and Imanaka, H. (1987b). FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. Journal of antibiotics. 40(9): 1249-1255.
10. Owens T. (1991). Requirement for noncognate interaction with T cells for the activation of B cell immunoglobulin secretion by IL-2. Cell Immunol 133:352-366.
11. Sakuma, S., Kato, Y., Nishigaki, F., Magari, K., Miyata, S., Ohkubo, Y., and Goto, T. (2001b). Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. International Immunopharmacology 1(4): 749-57.
12. Ulrich, P., Paul, G., Perentes, E., Mahl, A., and Roman D. (2004). Validation of immune function testing during a 4-week oral toxicity study with FK506. Toxicology Letters 149(1-3): 123-31.

13. Alessandro B, Paola S, Alberto E. Paneraic, Tiziana P, Paola Palanzaa and Stefano P(2003). Chronic psychosocial stress-induced down- regulation of immunity depends upon individual factors Journal of Neuroimmunology 141: 58–64
14. Donna C. S, Matthew J. S and Kimber L. W Jr. (2010) Systemic immunosuppression following a single pharyngeal aspiration of 1,2:5,6-dibenzanthracene in female B6C3F1 mice, Journal of Immunotoxicology, 7:3, 219-231